[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 7865
1. Fox KE, Colton LA, Erickson PF, Friedman JE, Cha HC, Keller P, MacDougald OA, Klemm DJ: Regulation of cyclin D1 and Wnt10b gene expression by cAMP-responsive element-binding protein during early adipogenesis involves differential promoter methylation. J Biol Chem; 2008 Dec 12;283(50):35096-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we tested the impact of CREB on expression of cyclin D1 and wingless-related mouse mammary tumor virus integration site 10b (Wnt10b) in 3T3-L1 cells.
  • Forced depletion of CREB blocked Bt(2)cAMP-stimulated cyclin D1 expression and basal Wnt10b gene expression.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):1008-20 [10629058.001]
  • [Cites] Cell. 1982 May;29(1):53-60 [7105184.001]
  • [Cites] Early Hum Dev. 1984 Sep;10(1-2):1-11 [6499712.001]
  • [Cites] J Pediatr. 1988 Jul;113(1 Pt 1):1-9 [3290412.001]
  • [Cites] Biol Cell. 1989;66(3):247-54 [2690986.001]
  • [Cites] Mol Endocrinol. 1992 Apr;6(4):647-55 [1350057.001]
  • [Cites] Annu Rev Nutr. 1992;12:207-33 [1503804.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2268-72 [7892260.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29847-53 [8939924.001]
  • [Cites] Oncol Res. 1997;9(4):205-11 [9268991.001]
  • [Cites] Nucleic Acids Res. 1998 Jan 1;26(1):362-7 [9399875.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):917-23 [9422750.001]
  • [Cites] Diabetes. 1999 Apr;48(4):685-90 [10102682.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1268-81 [15635092.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):601-11 [15895078.001]
  • [Cites] J Cell Sci. 2006 Mar 1;119(Pt 5):889-97 [16478789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13022-7 [16916928.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Dec;7(12):885-96 [17139329.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40341-53 [17071615.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2784-94 [17473212.001]
  • [Cites] Biochem Cell Biol. 2007 Aug;85(4):397-410 [17713575.001]
  • [Cites] Epigenetics. 2006 Oct-Dec;1(4):155-62 [17965621.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):612-7 [17997088.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 8;366(2):360-6 [18062916.001]
  • [Cites] Biochem Biophys Res Commun. 2008 May 30;370(2):289-94 [18374658.001]
  • [Cites] J Biol Chem. 2008 Jun 27;283(26):18002-11 [18408001.001]
  • [Cites] FEBS Lett. 2008 Sep 22;582(21-22):3201-5 [18708054.001]
  • [Cites] Science. 2000 Aug 11;289(5481):950-3 [10937998.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32649-57 [10915780.001]
  • [Cites] Trends Endocrinol Metab. 2000 May-Jun;11(4):142-8 [10754536.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28430-5 [11375992.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):179-83 [11557984.001]
  • [Cites] Obes Res. 2001 Sep;9(9):572-8 [11557838.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):1426-32 [11694510.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30998-1004 [12055200.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45420-7 [12213831.001]
  • [Cites] Obes Res. 2003 Jan;11(1):65-74 [12529487.001]
  • [Cites] Genes Dev. 2003 Jun 1;17(11):1352-65 [12782654.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 5;308(4):933-9 [12927809.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4471-8 [14593102.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):16927-38 [14764597.001]
  • [Cites] Diabetes. 2004 May;53(5):1243-52 [15111493.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3689-99 [15116100.001]
  • [Cites] Cell. 1979 Aug;17(4):771-9 [90553.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jan;79(2):480-4 [6176995.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1546-52 [10669732.001]
  • (PMID = 18957421.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK053969; United States / NIDDK NIH HHS / DK / DK51563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / Wnt10b protein, mouse; 136601-57-5 / Cyclin D1; EC 2.3.1.48 / CREB-Binding Protein
  • [Other-IDs] NLM/ PMC2596384
  •  go-up   go-down


2. Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A: Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res; 2010;12(3):R42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Breast cancer is a profoundly heterogeneous disease with respect to biologic and clinical behavior.
  • Unsupervised hierarchical clustering with 133 significant GISTIC regions revealed six genomic subtypes, termed 17q12, basal-complex, luminal-simple, luminal-complex, amplifier, and mixed subtypes.
  • Four of them had striking similarity to intrinsic gene-expression subtypes and showed associations to conventional tumor biomarkers and clinical outcome.
  • The basal-complex subtype displayed extensive genomic homogeneity and harbored the majority of BRCA1-mutated tumors.
  • These genomic subtypes may prove useful for understanding the mechanisms of tumor development and for prognostic and treatment prediction purposes.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / genetics. Comparative Genomic Hybridization. Gene Expression Profiling. Neoplasms, Basal Cell / classification. Neoplasms, Basal Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. BRCA1 Protein / genetics. BRCA2 Protein / genetics. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Follow-Up Studies. Genetic Predisposition to Disease. Humans. Middle Aged. Mutation / genetics. Oligonucleotide Array Sequence Analysis. Prognosis. Survival Rate


3. Kanellou P, Zaravinos A, Zioga M, Spandidos DA: Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma. Br J Dermatol; 2009 Jun;160(6):1215-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is a locally aggressive slowly growing tumour that rarely metastasizes and is mostly seen in older members of the population.
  • OBJECTIVES: To determine the involvement of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in BCC.
  • Moreover, we studied the mRNA expression levels of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in the BCC samples and compared them with mRNA levels in the corresponding normal tissue.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Expression Regulation, Neoplastic / genetics. Genes, Tumor Suppressor / physiology. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p15 / genetics. DNA Mutational Analysis / methods. Female. Genes, p16. Genes, p53. Heterozygote. Humans. Loss of Heterozygosity. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Polymerase Chain Reaction / methods. RNA, Messenger / metabolism. Statistics as Topic. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298278.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


Advertisement
4. Keese M, Magdeburg RJ, Herzog T, Hasenberg T, Offterdinger M, Pepperkok R, Sturm JW, Bastiaens PI: Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. J Biol Chem; 2005 Jul 29;280(30):27826-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In tumor cells, high phosphorylation levels of receptor tyrosine kinases may occur in the absence of exogenous ligands due to autocrine signaling or enhanced tyrosine kinase activity.
  • Here we show that the phosphorylation state of the endogenous epidermal growth factor receptor (EGFR) can be quantitatively imaged in tumor cells and tissues by detecting fluorescence resonance energy transfer between fluorophores conjugated to antibodies against the receptor and phosphotyrosine, respectively.
  • Five different human colorectal cell lines were analyzed for activity and expression of EGFR.
  • All cell lines exhibited basal EGFR phosphorylation under serum starvation conditions.
  • Phosphorylation levels increased after stimulation with EGF or pervanadate, dependent on the level of basal EGFR phosphorylation in the respective cell lines.
  • This basal activity correlated inversely with receptor expression.
  • Using the acceptor photobleaching fluorescence resonance energy transfer imaging approach, a significantly higher phosphorylation state of EGFR was also found in resected human colorectal tumor samples as compared with adjacent healthy tissue.
  • Imaging of EGFR phosphorylation may thus serve as a valuable tool to investigate the role of receptor tyrosine kinase activity in malignant cell growth.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Fluorescence Resonance Energy Transfer / methods. Microscopy, Confocal / methods. Receptor, Epidermal Growth Factor / chemistry
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Cloning, Molecular. Culture Media, Serum-Free / pharmacology. DNA, Complementary / metabolism. Enzyme-Linked Immunosorbent Assay. Humans. Immunoblotting. Immunoprecipitation. Kinetics. Microscopy, Fluorescence. Phosphorylation. Phosphotyrosine / metabolism. RNA / metabolism. Receptor Protein-Tyrosine Kinases / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Time Factors. Vanadates / pharmacology


5. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW: Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab; 2009 Oct;94(10):4107-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: The MEK inhibitor AZD6244 (ARRY-142886) and mTOR inhibitor rapamycin were tested separately and in combination in 10 differentiated thyroid cancer and anaplastic thyroid cancer cell lines and in a xenograft model for evidence of pathway inhibition, growth inhibition, apoptosis, and long-range adaptation and resistance.
  • RESULTS: Seven of 10 tested lines had evidence of significant basal activity of the PI-3K/AKT/mTOR pathway, with elevated phosphorylated AKT and phosphorylated p70 S6 kinase.
  • Dual-pathway inhibition in the Ret-PTC mutant cell line TPC1 caused an intense G(1) arrest in cell culture and reversible cytostatic inhibition in a xenograft model.


6. deSousa JL, Leibovitch I, Malhotra R, O'Donnell B, Sullivan T, Selva D: Techniques and outcomes of total upper and lower eyelid reconstruction. Arch Ophthalmol; 2007 Dec;125(12):1601-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Six cases were identified, 1 following trauma and 5 following tumor excision (4 with basal cell carcinoma and 1 with melanoma).
  • Following tumor excision, bilamellar repair was performed using composite grafts for the posterior lamella and skin-muscle flaps for the anterior lamella.

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071107.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


7. Wolf IH, Kodama K, Cerroni L, Kerl H: Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol; 2007 Jun;29(3):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical imiquimod (IQ) is an effective treatment for genital warts and various malignant tumors of the skin.
  • We investigated the composition of the inflammatory cell infiltrate before, during, and after the treatment of 10 superficial cutaneous malignancies (melanoma in situ (n = 4), melanoma metastasis (n = 1), squamous cell carcinoma in situ (n = 4), and basal cell carcinoma (n = 1) with 5% IQ cream.
  • These findings further support previous investigations that the antitumor effects of IQ result from an enhanced cytotoxic T-cell mediated immune response and from the recruitment of plasmacytoid dendritic cells to the skin.
  • The population of infiltrative inflammatory cells was similar in all patients irrespective of the type of tumor.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Inflammation / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Bowen's Disease / chemistry. Bowen's Disease / drug therapy. Bowen's Disease / pathology. Carcinoma in Situ / chemistry. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Female. Humans. Hutchinson's Melanotic Freckle / chemistry. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / pathology. Keratosis / drug therapy. Keratosis / metabolism. Keratosis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519620.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Biomarkers, Tumor; 99011-02-6 / imiquimod
  •  go-up   go-down


8. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST: Mast cells and cutaneous malignancies. Mod Pathol; 2006 Jan;19(1):149-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma.
  • These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma.
  • Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix.
  • Mast cell proteases reorganize the stroma to facilitate endothelial cell migration.
  • As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells.
  • Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in tumor biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.
  • [MeSH-major] Mast Cells / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / pathology. Humans. Melanoma / blood. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258517.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 71
  •  go-up   go-down


9. Kurzik-Dumke U, Hörner M, Czaja J, Nicotra MR, Simiantonaki N, Koslowski M, Natali PG: Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor. Int J Mol Med; 2008 Jan;21(1):19-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor.
  • Recently, we identified htid-1, the human counterpart of the Drosophila tumor suppressor gene lethal(2)tumorous imaginal discs [l(2)tid], as a direct molecular ligand of the adenomatous polyposis coli (APC) tumor suppressor.
  • Furthermore, we showed that the protein products of the two tumor suppressors co-localized in the basal and apical region of normal colon epithelia and that loss of differentiation capacity of colorectal cancers correlated with a shift in their expression patterns from compartmentalized to diffuse cytoplasmic.
  • Since the Tid proteins are members of the DnaJ-like protein family, an essential component of the Hsp70/Hsc70 chaperone machinery, our findings describe a novel, causal link between the function of chaperone machines, APC-mediated Wg/Wnt signaling and tumor development.
  • [MeSH-major] Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Gene Expression Regulation, Neoplastic. HSP40 Heat-Shock Proteins / genetics. HSP40 Heat-Shock Proteins / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Adenomatous Polyposis Coli Protein / metabolism. Antibodies, Neoplasm. Cell Differentiation. DNA Primers. Disease Progression. HSP70 Heat-Shock Proteins / metabolism. Humans. Intestinal Mucosa / pathology. RNA Splicing. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097612.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Antibodies, Neoplasm; 0 / DNA Primers; 0 / DNAJA3 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / HSP70 Heat-Shock Proteins; 0 / RNA, Neoplasm; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


10. Dugani CB, Paquin A, Fujitani M, Kaplan DR, Miller FD: p63 antagonizes p53 to promote the survival of embryonic neural precursor cells. J Neurosci; 2009 May 20;29(20):6710-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we have asked whether the p53 family member p63 plays any role during this developmental window, focusing on the embryonic cerebral cortex.
  • This cortical precursor apoptosis is the consequence of deregulated p53 activity, since both basal precursor apoptosis and that induced by loss of p63 are rescued by coincident genetic silencing of p53.
  • [MeSH-major] Cell Differentiation / physiology. Cerebral Cortex / cytology. Embryonic Stem Cells / physiology. Neurons / physiology. Phosphoproteins / physiology. Trans-Activators / physiology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Analysis of Variance. Animals. Caspase 3 / metabolism. Cell Count / methods. Cell Survival / genetics. Cells, Cultured. DNA-Binding Proteins / deficiency. Electroporation / methods. Embryo, Mammalian. Female. Gene Expression Regulation, Developmental / genetics. Gene Expression Regulation, Developmental / physiology. Green Fluorescent Proteins / genetics. Humans. Mice. Mice, Inbred C57BL. Mice, Knockout. Mutation / genetics. Nuclear Proteins / deficiency. Pregnancy. RNA, Small Interfering / metabolism. Tubulin / metabolism. Tumor Suppressor Proteins / deficiency

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458240.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / RNA, Small Interfering; 0 / Trans-Activators; 0 / Trp63 protein, mouse; 0 / Tubulin; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / enhanced green fluorescent protein; 0 / tumor suppressor protein p73; 147336-22-9 / Green Fluorescent Proteins; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


11. Zhang XL, Selbi W, de la Motte C, Hascall V, Phillips AO: Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-beta1 generation in renal proximal tubular epithelial cells. J Am Soc Nephrol; 2005 Jan;16(1):79-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been demonstrated that bone morphogenic protein-7 (BMP-7) stimulates formation of hyaluronan (HA)-based cables on the cell surface of renal proximal tubular cells and that these cables mediate monocyte binding.
  • Furthermore, interaction of monocytes with proximal tubule cell (PTC) surface intracellular adhesion molecule (ICAM) stimulates the synthesis of TGF-beta1.
  • This study examined the effect of BMP-7 on monocyte-stimulated TGF-beta1 synthesis under conditions of basal and stimulated ICAM expression.
  • Removal of cell surface HA or inhibition of monocyte interaction with HA using antibody to CD44 prevented this effect of BMP-7.
  • Although stimulation of PTC by BMP-7 alone decreased cell surface ICAM expression, it did not affect TNF-alpha-induced ICAM expression.
  • The effect of BMP-7 on TGF-beta1 synthesis in TNF-alpha-stimulated cells was abrogated by disruption of CD44-HA interactions, suggesting that it was due to increased monocyte binding to HA on the cell surface.
  • [MeSH-minor] Antigens, CD44 / metabolism. Bone Morphogenetic Protein 7. Cell Adhesion / immunology. Humans. Hyaluronic Acid / metabolism. Intercellular Adhesion Molecule-1 / metabolism. Transcription, Genetic. Transforming Growth Factor beta1. Tumor Necrosis Factor-alpha / pharmacology. U937 Cells

  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Soc Nephrol. 2005 Jan;16(1):9-11 [15574504.001]
  • (PMID = 15574511.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / BMP7 protein, human; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins; 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


12. Li DQ, Chen Z, Song XJ, de Paiva CS, Kim HS, Pflugfelder SC: Partial enrichment of a population of human limbal epithelial cells with putative stem cell properties based on collagen type IV adhesiveness. Exp Eye Res; 2005 Apr;80(4):581-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial enrichment of a population of human limbal epithelial cells with putative stem cell properties based on collagen type IV adhesiveness.
  • This study was an initial attempt to isolate a population of human limbal epithelial cells enriched for certain putative stem cell properties based on their phenotype.
  • The rapidly adherent cells (RAC), slowly adherent cells and non-adherent cells were evaluated for certain stem cell properties: (a) BrdU-label retention, (b) expression of basal cell (integrin beta1, p63, ABCG2) and differentiation (involucrin, keratin 12) markers, and (c) colony forming efficiency (CFE) and growth capacity on a 3T3 fibroblast feeder layer.
  • These findings demonstrated for the first time that human limbal epithelial cells with stem cell properties can be partially enriched by their adhesiveness to collagen IV.
  • The RAC population enriched for certain putative stem cell properties may prove useful in the future for transplantation to diseased and damaged corneas with limbal stem cell deficiency.
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette Transporters / analysis. Adult. Aged. Biomarkers / analysis. Bromodeoxyuridine / analysis. Cell Adhesion / physiology. Cell Division / physiology. Cells, Cultured. DNA-Binding Proteins. Epithelial Cells / physiology. Genes, Tumor Suppressor. Humans. Integrin beta1 / analysis. Keratin-12. Keratins / analysis. Middle Aged. Neoplasm Proteins / analysis. Phenotype. Phosphoproteins / analysis. Protein Precursors / analysis. RNA, Messenger / analysis. Trans-Activators / analysis. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Mol Biol Cell. 2000 Feb;11(2):453-66 [10679006.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1427-30 [10688781.001]
  • [Cites] Surv Ophthalmol. 2000 Mar-Apr;44(5):415-25 [10734241.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):86-93 [10891515.001]
  • [Cites] Cornea. 2000 Jul;19(4):421-6 [10928750.001]
  • [Cites] Hum Gene Ther. 2000 Nov 1;11(16):2261-6 [11084684.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13473-5 [11087834.001]
  • [Cites] Cornea. 2001 Jan;20(1):81-5 [11189010.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61 [11248048.001]
  • [Cites] Cell. 2001 Jun 29;105(7):829-41 [11439179.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] Ophthalmology. 2001 Sep;108(9):1569-74 [11535452.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3865-72 [11719553.001]
  • [Cites] Blood. 2002 Jan 15;99(2):507-12 [11781231.001]
  • [Cites] Exp Eye Res. 2001 Oct;73(4):449-59 [11825017.001]
  • [Cites] J Immunol Methods. 2002 Sep 15;267(2):109-17 [12165432.001]
  • [Cites] J Invest Dermatol. 2002 Oct;119(4):888-99 [12406335.001]
  • [Cites] Neuroreport. 2002 Nov 15;13(16):2059-63 [12438926.001]
  • [Cites] J Cell Sci. 2003 Oct 15;116(Pt 20):4239-48 [12953062.001]
  • [Cites] Stem Cells. 2004;22(3):355-66 [15153612.001]
  • [Cites] Exp Eye Res. 2004 Jul;79(1):41-9 [15183099.001]
  • [Cites] Cell. 1975 Nov;6(3):331-43 [1052771.001]
  • [Cites] J Dent Res. 1981 Aug;60 Spec No C:1611-20 [6943171.001]
  • [Cites] Science. 1982 Mar 5;215(4537):1239-41 [7058342.001]
  • [Cites] J Cell Biol. 1986 Jul;103(1):49-62 [2424919.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(8):2302-6 [2436229.001]
  • [Cites] Cell. 1989 Apr 21;57(2):201-9 [2702690.001]
  • [Cites] Eye (Lond). 1989;3 ( Pt 2):141-57 [2695347.001]
  • [Cites] Cell. 1993 May 21;73(4):713-24 [8500165.001]
  • [Cites] Cell. 1995 Jan 13;80(1):83-93 [7813021.001]
  • [Cites] J Cell Physiol. 1995 Apr;163(1):61-79 [7896901.001]
  • [Cites] Clin Sci (Lond). 1996 Aug;91(2):141-6 [8795436.001]
  • [Cites] Curr Eye Res. 1996 Sep;15(9):973-84 [8921219.001]
  • [Cites] Lancet. 1997 Apr 5;349(9057):990-3 [9100626.001]
  • [Cites] Breast Cancer Res Treat. 1998 May;49(2):155-64 [9696398.001]
  • [Cites] J Cell Sci. 1998 Oct;111 ( Pt 19):2867-75 [9730979.001]
  • [Cites] Exp Cell Res. 1998 Oct 10;244(1):184-95 [9770361.001]
  • [Cites] Exp Dermatol. 1999 Feb;8(1):80-8 [10206725.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] J Cell Biol. 1999 May 17;145(4):769-82 [10330405.001]
  • (PMID = 15781286.001).
  • [ISSN] 0014-4835
  • [Journal-full-title] Experimental eye research
  • [ISO-abbreviation] Exp. Eye Res.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / R03 EY014553-01; United States / NEI NIH HHS / EY / EY11915; United States / NEI NIH HHS / EY / R03 EY014553; United States / NEI NIH HHS / EY / R01 EY011915; United States / NEI NIH HHS / EY / EY014553
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Biomarkers; 0 / Collagen Type IV; 0 / DNA-Binding Proteins; 0 / Integrin beta1; 0 / KRT12 protein, human; 0 / Keratin-12; 0 / Neoplasm Proteins; 0 / Phosphoproteins; 0 / Protein Precursors; 0 / RNA, Messenger; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 60108-77-2 / involucrin; 68238-35-7 / Keratins; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ NIHMS211937; NLM/ PMC2906384
  •  go-up   go-down


13. Brinckmann S, Kim JY, Greer JR: Fundamental differences in mechanical behavior between two types of crystals at the nanoscale. Phys Rev Lett; 2008 Apr 18;100(15):155502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fundamental differences in mechanical behavior between two types of crystals at the nanoscale.
  • We present differences in the mechanical behavior of nanoscale gold and molybdenum single crystals.
  • A significant strength increase is observed as the size is reduced to 100 nm.
  • Both nanocrystals exhibit discrete strain bursts during plastic deformation.
  • We postulate that they arise from significant differences in the dislocation behavior.
  • Dislocation starvation is the predominant mechanism of plasticity in nanoscale fcc crystals, while junction formation and hardening characterize bcc plasticity.
  • A statistical analysis of strain bursts is performed as a function of size and compared with stochastic models.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518121.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Altan-Yaycioglu R, Bolat F, Akova YA: Basosquamous carcinoma of the lacrimal sac: a case report. Orbit; 2007 Dec;26(4):267-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological examination revealed basal cell carcinoma of the lacrimal sac.
  • Two weeks later, the diseased sac and surrounding tissue were excised, using frozen sections to ensure adequate tumor-free margins.
  • The lacrimal sac tumor was diagnosed as basal cell carcinoma with focal squamous differentiation.
  • No tumor recurrence was detected in 1.5 years of follow-up.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097965.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Corrêa Mde P, Ferreira AP, Gollner AM, Rodrigues MF, Guerra MC: [Markers expression of cell proliferation and apoptosis in basal cell carcinoma]. An Bras Dermatol; 2009 Nov-Dec;84(6):606-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Markers expression of cell proliferation and apoptosis in basal cell carcinoma].
  • [Transliterated title] Expressão de marcadores de proliferação celular e apoptose em carcinoma basocelular.
  • BACKGROUND: - Basal cell carcinoma is the most common form of human cancer.
  • OBJECTIVE - To correlate markers expression of apoptosis (p53 and bcl-2) and cell proliferation (Ki-67 and PCNA) with histological indicators of tumor severity.
  • The Mann-Whitney test was used to compare these markers expression with the manifestation form of basal cell carcinoma.
  • RESULTS - Bcl-2 expression was significant in basal cell carcinomas said to be aggressive (morpheaform and nodular types).
  • Of the studied tumors, 66.7% (n =10) strongly expressed p53.Our results show a greater expression of Ki-67 in nodular and superficial basal cell carcinoma, with no expression in the controls.
  • CONCLUSION - The findings allow us to conclude that Bcl-2 and p53 show a tendency to indicate the severity of basal cell carcinoma.
  • Also, PCNA was not a good marker of cell proliferation.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Cell Proliferation. Skin Neoplasms / chemistry. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191172.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Maire C, Delesalle F, Carpentier O, Lequint P, Delaporte E, Thomas P: [Multiple basal cell carcinomas after etanercept treatment for psoriasis]. Ann Dermatol Venereol; 2009 Apr;136(4):355-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple basal cell carcinomas after etanercept treatment for psoriasis].
  • [Transliterated title] Carcinomes basocellulaires multiples après traitement d'un psoriasis par étanercept.
  • BACKGROUND: Several cases of skin cancer have been reported after treatment with etanercept although the causal relationship remains uncertain.
  • We report the case of a patient who rapidly developed multiple basal cell carcinomas (BCC) after discontinuation of this treatment.
  • [MeSH-major] Carcinoma, Basal Cell / chemically induced. Carcinoma, Basal Cell / radionuclide imaging. Immunoglobulin G / therapeutic use. Psoriasis / drug therapy. Receptors, Tumor Necrosis Factor / therapeutic use. Skin Neoplasms / chemically induced. Skin Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Etanercept .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361704.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


17. Larizza D, Calcaterra V, Sampaolo P, Lanati G, Brambilla P, Mondello T, Cesari S: Unusual presentation of juvenile granulosa cell tumor of the ovary. J Endocrinol Invest; 2006 Jul-Aug;29(7):653-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of juvenile granulosa cell tumor of the ovary.
  • BACKGROUND: We present a case report of juvenile granulosa cell tumor of the ovary (JGCT) with an unusual clinical presentation and hormonal secretion.
  • Endocrinological evaluation after the operation showed that 17OH-P, insulin and basal FSH and LH serum values had returned to normal, while DHEA levels had decreased to within the upper limit of the normal range.
  • [MeSH-major] Granulosa Cell Tumor / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Obstet Gynaecol Res. 2004 Dec;30(6):439-43 [15566459.001]
  • [Cites] J Pediatr Surg. 1997 May;32(5):762-5 [9165474.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):389-91 [11531301.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):235-40 [15589608.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):517-21 [14528083.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):323-7 [9988794.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):447-52 [9190974.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]
  • [Cites] Eur J Clin Nutr. 1997 Jan;51(1):6-10 [9023460.001]
  • [Cites] Pediatr Pathol. 1993 Sep-Oct;13(5):549-58 [8247952.001]
  • [Cites] Arch Dis Child. 1969 Jun;44(235):291-303 [5785179.001]
  • [Cites] Arch Pathol Lab Med. 1984 Oct;108(10):786-91 [6548120.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jul;191(1):366-7 [15295395.001]
  • [Cites] Reprod Biomed Online. 2005 Jun;10(6):786-812 [15970011.001]
  • [Cites] N Engl J Med. 1989 Sep 21;321(12):790-3 [2770810.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jul;19(3):266-71 [10907176.001]
  • [Cites] Arch Fr Pediatr. 1992 Nov;49(9):793-8 [1300967.001]
  • [Cites] Arch Dis Child. 1966 Dec;41(220):613-35 [5927918.001]
  • (PMID = 16957416.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 3XMK78S47O / Testosterone; 459AG36T1B / Dehydroepiandrosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


18. Sun Y, Fang Y, Yoon MS, Zhang C, Roccio M, Zwartkruis FJ, Armstrong M, Brown HA, Chen J: Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci U S A; 2008 Jun 17;105(24):8286-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mammalian target of rapamycin (mTOR) assembles a signaling network essential for the regulation of cell growth, which has emerged as a major target of anticancer therapies.
  • Furthermore, the overexpression of TSC2 suppresses PLD1 activation, whereas the knockdown or deletion of TSC2 leads to elevated basal activity of PLD.
  • [MeSH-minor] Cell Line. Humans. RNA Interference. RNA, Small Nuclear / genetics. Signal Transduction. TOR Serine-Threonine Kinases. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 May 5;275(18):13406-10 [10747847.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):657-64 [16170341.001]
  • [Cites] Mol Biol Cell. 2000 Dec;11(12):4359-68 [11102529.001]
  • [Cites] Science. 2001 Nov 30;294(5548):1942-5 [11729323.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6356-65 [12214276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6 [12271141.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):578-81 [12771962.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3937-42 [12813467.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4741-6 [16537399.001]
  • [Cites] Cell Signal. 2006 Dec;18(12):2283-91 [16837165.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):1-4 [17210675.001]
  • [Cites] Science. 2007 Nov 9;318(5852):977-80 [17991864.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):708-15 [17993646.001]
  • [Cites] J Cell Sci. 2008 Feb 1;121(Pt 3):282-9 [18198186.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1457-66 [12820960.001]
  • [Cites] Genes Dev. 2003 Aug 1;17(15):1829-34 [12869586.001]
  • [Cites] Curr Biol. 2003 Aug 5;13(15):1259-68 [12906785.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32493-6 [12842888.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39921-30 [12869548.001]
  • [Cites] Trends Biochem Sci. 2003 Nov;28(11):573-6 [14607085.001]
  • [Cites] Curr Biol. 2003 Dec 2;13(23):2037-44 [14653992.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):32-8 [14729330.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(18):7965-75 [15340059.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1137-44 [8261513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9154-9 [8799170.001]
  • [Cites] Anal Biochem. 1997 Oct 1;252(1):1-9 [9324933.001]
  • [Cites] J Cell Biol. 1998 Jan 12;140(1):81-90 [9425156.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3632-7 [9520417.001]
  • [Cites] Biochim Biophys Acta. 1999 Jul 30;1439(2):121-33 [10425390.001]
  • [Cites] Biochim Biophys Acta. 1999 Jul 30;1439(2):175-86 [10425394.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):702-13 [15854902.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18717-27 [15772076.001]
  • [Cites] FEBS J. 2005 Aug;272(15):3929-37 [16045763.001]
  • [Cites] J Biol Chem. 2005 Sep 23;280(38):33076-82 [16049009.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14238-43 [16176982.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Biochim Biophys Acta. 2000 May 31;1485(2-3):153-62 [10832096.001]
  • (PMID = 18550814.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuropeptides; 0 / RHEB protein, human; 0 / RNA, Small Nuclear; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 3.1.4.4 / Phospholipase D; EC 3.1.4.4 / phospholipase D1; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2448829
  •  go-up   go-down


19. Colton SL, Xu XS, Wang YA, Wang G: The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment. J Biol Chem; 2006 Sep 15;281(37):27117-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment.
  • DNA damage can lead to either DNA repair with cell survival or to apoptotic cell death.
  • Although the biochemical processes underlying DNA repair and apoptosis have been extensively studied, the mechanisms by which cells determine whether the damage will be repaired or the apoptotic pathway will be activated is largely unknown.
  • We have studied the role of nucleotide excision repair (NER) in cisplatin DNA damage-induced apoptotic cell death using both normal human fibroblasts and NER-defective xeroderma pigmentosum (XP) XPA and XPG cells.
  • The flow cytometry experiment revealed an altered cell cycle arrest pattern of the NER-defective cells following cisplatin treatment.
  • The results obtained from our immunoprecipitation experiment further demonstrated that the ATM protein interacted with the TFIIH basal transcription factor and the XPG protein of the NER pathway.
  • [MeSH-major] Cell Cycle Proteins / chemistry. Cisplatin / pharmacology. DNA Repair. DNA-Binding Proteins / chemistry. Nucleotides / chemistry. Protein-Serine-Threonine Kinases / chemistry. Tumor Suppressor Proteins / chemistry
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis. Ataxia Telangiectasia Mutated Proteins. Caspase 3. Caspases / metabolism. Cell Survival. DNA Damage. Enzyme Activation. Fibroblasts / metabolism. Humans. Phosphorylation. Protein Kinases / metabolism

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Biol Chem. 2007 Feb 9;282(6):4232
  • (PMID = 16849332.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES06639; United States / NIEHS NIH HHS / ES / R01ES09699; United States / NIEHS NIH HHS / ES / T32 ES01216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nucleotides; 0 / Tumor Suppressor Proteins; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Checkpoint kinase 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Jarry H, Thelen P, Christoffel V, Spengler B, Wuttke W: Cimicifuga racemosa extract BNO 1055 inhibits proliferation of the human prostate cancer cell line LNCaP. Phytomedicine; 2005 Mar;12(3):178-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cimicifuga racemosa extract BNO 1055 inhibits proliferation of the human prostate cancer cell line LNCaP.
  • Extracts from black cohosh (Cimicifuga racemosa, CR) exert an anti-proliferative action in human breast cancer cell cultures, which has been attributed to an anti-estrogenic effect.
  • Thus, the anti-tumor effect of CR me be mediated by mechanisms not involving these receptors.
  • Since activation of the AhR causes inhibition of growth of prostate cancer cells, we addressed the question, whether CR may not only inhibit growth of breast cancer--but also of prostate cancer cells.
  • Under basal as well as under estradiol- and dihydrotestosterone stimulated conditions, the CR extract dose dependently inhibited proliferation of LNCaP cells.
  • A significant reduction of cell growth was observed at a concentration as low as 50 ng/ml.
  • [MeSH-minor] Cell Line, Tumor / drug effects. Chromatography, High Pressure Liquid. Humans. Male. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Rhizome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830838.001).
  • [ISSN] 0944-7113
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cimicifuga extract BNO 1055; 0 / Plant Extracts
  •  go-up   go-down


21. Amnuaykanjanasin A, Punya J, Paungmoung P, Rungrod A, Tachaleat A, Pongpattanakitshote S, Cheevadhanarak S, Tanticharoen M: Diversity of type I polyketide synthase genes in the wood-decay fungus Xylaria sp. BCC 1067. FEMS Microbiol Lett; 2005 Oct 1;251(1):125-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The finding of 11 distinct PKS genes solely by means of PCR cloning supports that PKS genes are highly diverse in fungi.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] FEMS Microbiol Lett. 2006 Jan;254(2):333
  • (PMID = 16112817.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF395534/ AY445825/ AY965071/ AY971512/ AY971872/ DQ003485/ DQ011042/ DQ011043/ DQ011045/ DQ011595/ DQ011596
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Fungal; 0 / Fungal Proteins; 79956-01-7 / Polyketide Synthases
  •  go-up   go-down


22. Davidchack RL, Laird BB: Crystal structure and interaction dependence of the crystal-melt interfacial free energy. Phys Rev Lett; 2005 Mar 4;94(8):086102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crystal structure and interaction dependence of the crystal-melt interfacial free energy.
  • We examine via molecular simulation the dependence of the crystal-melt interfacial free energy gamma on molecular interaction and crystal structure (fcc vs bcc) for systems interacting with inverse-power repulsive potentials, u(r)=epsilon(sigma/r)(n), 6< or =n< or =100.
  • Both the magnitude and anisotropy of gamma are found to increase as the range of the potential increases.
  • Also we find that gamma(bcc)<gamma(fcc), consistent with recent observations that some fcc forming fluids nucleate via formation of metastable bcc nuclei.
  • The anisotropy in gamma is also seen to be smaller in the bcc systems.
  • By extrapolation, we also obtain an improved estimate of gamma for hard spheres.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783906.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kwon S, Kim TS, Yu GH, Jung JH, Park HD: Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing. J Microbiol Biotechnol; 2010 Dec;20(12):1717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing.
  • The integrated fixed-film activated sludge (IFAS) system is a variation of the activated sludge wastewater treatment process, in which hybrid suspended and attached biomass is used to treat wastewater.
  • Although the function and performance of the IFAS system are well studied, little is known about its microbial community structure.
  • In this study, the composition and diversity of the bacterial community of suspended and attached biomass samples were investigated in a full-scale IFAS system using a highthroughput pyrosequencing technology.
  • Distinct bacterial community compositions were examined for each sample and appeared to be important for its features different from conventional activated sludge processes.
  • The abundant bacterial groups were Betaproteobacteria (59.3%), Gammaproteobacteria (8.1%), Bacteroidetes (5.2%), Alphaproteobacteria (3.9%), and Actinobacteria (3.2%) in the suspended sample, whereas Actinobacteria (14.6%), Firmicutes (13.6%), Bacteroidetes (11.6%), Betaproteobacteria (9.9%), Gammaproteobacteria (9.25%), and Alphaproteobacteria (7.4%) were major bacterial groups in the attached sample.
  • Regarding the diversity, totals of 3,034 and 1,451 operational taxonomic units were identified at the 3% cutoff for the suspended and attached samples, respectively.
  • Rank abundance and community analyses demonstrated that most of the diversity was originated from rare species in the samples.
  • Taken together, the information obtained in this study will be a base for further studies relating to the microbial community structure and function of the IFAS system.
  • [MeSH-major] Bacteria / classification. Bacteria / genetics. Biodiversity. Sewage / microbiology
  • [MeSH-minor] Cluster Analysis. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. DNA, Ribosomal / chemistry. DNA, Ribosomal / genetics. Molecular Sequence Data. Phylogeny. RNA, Ribosomal, 16S / genetics. Sequence Analysis, DNA. Water Purification

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21193829.001).
  • [ISSN] 1738-8872
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GU539392/ GU539393/ GU539394/ GU539395/ GU539396/ GU539397/ GU539398/ GU539399/ GU539400/ GU539401/ GU539402/ GU539403/ GU539404/ GU539405/ GU539406/ GU539407/ GU539408/ GU539409/ GU539410/ GU539411/ GU539412/ GU539413/ GU539414/ GU539415/ GU539416/ GU539417/ GU539418/ GU539419/ GU539420/ GU539421/ GU539422/ GU539423/ GU539424/ GU539425/ GU539426/ GU539427/ GU539428/ GU539429/ GU539430/ GU539431/ GU539432/ GU539433/ GU539434/ GU539435/ GU539436/ GU539437/ GU539438/ GU539439/ GU539440/ GU539441/ GU539442/ GU539443/ GU539444/ GU539445/ GU539446/ GU539447/ GU539448/ GU539449/ GU539450/ GU539451/ GU539452/ GU539453/ GU539454/ GU539455/ GU539456/ GU539457/ GU539458/ GU539459/ GU539460/ GU539461/ GU539462/ GU539463/ GU539464/ GU539465/ GU539466/ GU539467/ GU539468/ GU539469/ GU539470/ GU539471/ GU539472/ GU539473/ GU539474/ GU539475/ GU539476/ GU539477/ GU539478/ GU539479/ GU539480/ GU539481/ GU539482/ GU539483/ GU539484/ GU539485/ GU539486/ GU539487/ GU539488/ GU539489/ GU539490/ GU539491/ GU539492/ GU539493/ GU539494/ GU539495/ GU539496/ GU539497/ GU539498/ GU539499/ GU539500/ GU539501/ GU539502/ GU539503/ GU539504/ GU539505/ GU539506/ GU539507/ GU539508/ GU539509/ GU539510/ GU539511/ GU539512/ GU539513/ GU539514/ GU539515/ GU539516/ GU539517/ GU539518/ GU539519/ GU539520/ GU539521/ GU539522/ GU539523/ GU539524/ GU539525/ GU539526/ GU539527/ GU539528/ GU539529/ GU539530/ GU539531/ GU539532/ GU539533/ GU539534/ GU539535/ GU539536/ GU539537/ GU539538/ GU539539/ GU539540/ GU539541/ GU539542/ GU539543/ GU539544/ GU539545/ GU539546/ GU539547/ GU539548/ GU539549/ GU539550/ GU539551/ GU539552/ GU539553/ GU539554/ GU539555/ GU539556/ GU539557/ GU539558/ GU539559/ GU539560/ GU539561/ GU539562/ GU539563/ GU539564/ GU539565/ GU539566/ GU539567/ GU539568/ GU539569/ GU539570/ GU539571/ GU539572/ GU539573/ GU539574/ GU539575/ GU539576/ GU539577/ GU539578/ GU539579/ GU539580/ GU539581/ GU539582/ GU539583/ GU539584/ GU539585/ GU539586/ GU539587/ GU539588/ GU539589/ GU539590/ GU539591/ GU539592/ GU539593/ GU539594/ GU539595/ GU539596/ GU539597/ GU539598/ GU539599/ GU539600/ GU539601/ GU539602/ GU539603/ GU539604/ GU539605/ GU539606/ GU539607/ GU539608/ GU539609/ GU539610/ GU539611/ GU539612/ GU539613/ GU539614/ GU539615/ GU539616/ GU539617/ GU539618/ GU539619/ GU539620/ GU539621/ GU539622/ GU539623/ GU539624/ GU539625/ GU539626/ GU539627/ GU539628/ GU539629/ GU539630/ GU539631/ GU539632/ GU539633/ GU539634/ GU539635/ GU539636/ GU539637/ GU539638/ GU539639/ GU539640/ GU539641/ GU539642/ GU539643/ GU539644/ GU539645/ GU539646/ GU539647/ GU539648/ GU539649/ GU539650/ GU539651/ GU539652/ GU539653/ GU539654/ GU539655/ GU539656/ GU539657/ GU539658/ GU539659/ GU539660/ GU539661/ GU539662/ GU539663/ GU539664/ GU539665/ GU539666/ GU539667/ GU539668/ GU539669/ GU539670/ GU539671/ GU539672/ GU539673/ GU539674/ GU539675/ GU539676/ GU539677/ GU539678/ GU539679/ GU539680/ GU539681/ GU539682/ GU539683/ GU539684/ GU539685/ GU539686/ GU539687/ GU539688/ GU539689/ GU539690/ GU539691/ GU539692/ GU539693/ GU539694/ GU539695/ GU539696/ GU539697/ GU539698/ GU539699/ GU539700/ GU539701/ GU539702/ GU539703/ GU539704/ GU539705/ GU539706/ GU539707/ GU539708/ GU539709/ GU539710/ GU539711/ GU539712/ GU539713/ GU539714/ GU539715/ GU539716/ GU539717/ GU539718/ GU539719/ GU539720/ GU539721/ GU539722/ GU539723/ GU539724/ GU539725/ GU539726/ GU539727/ GU539728/ GU539729/ GU539730/ GU539731/ GU539732/ GU539733/ GU539734/ GU539735/ GU539736/ GU539737/ GU539738/ GU539739/ GU539740/ GU539741/ GU539742/ GU539743/ GU539744/ GU539745/ GU539746/ GU539747/ GU539748/ GU539749/ GU539750/ GU539751/ GU539752/ GU539753/ GU539754/ GU539755/ GU539756/ GU539757/ GU539758/ GU539759/ GU539760/ GU539761/ GU539762/ GU539763/ GU539764/ GU539765/ GU539766/ GU539767/ GU539768/ GU539769/ GU539770/ GU539771/ GU539772/ GU539773/ GU539774/ GU539775/ GU539776/ GU539777/ GU539778/ GU539779/ GU539780/ GU539781/ GU539782/ GU539783/ GU539784/ GU539785/ GU539786/ GU539787/ GU539788/ GU539789/ GU539790/ GU539791/ GU539792/ GU539793/ GU539794/ GU539795/ GU539796/ GU539797/ GU539798/ GU539799/ GU539800/ GU539801/ GU539802/ GU539803/ GU539804/ GU539805/ GU539806/ GU539807/ GU539808/ GU539809/ GU539810/ GU539811/ GU539812/ GU539813/ GU539814/ GU539815/ GU539816/ GU539817/ GU539818/ GU539819/ GU539820/ GU539821/ GU539822/ GU539823/ GU539824/ GU539825/ GU539826/ GU539827/ GU539828/ GU539829/ GU539830/ GU539831/ GU539832/ GU539833/ GU539834/ GU539835/ GU539836/ GU539837/ GU539838/ GU539839/ GU539840/ GU539841/ GU539842/ GU539843/ GU539844/ GU539845/ GU539846/ GU539847/ GU539848/ GU539849/ GU539850/ GU539851/ GU539852/ GU539853/ GU539854/ GU539855/ GU539856/ GU539857/ GU539858/ GU539859/ GU539860/ GU539861/ GU539862/ GU539863/ GU539864/ GU539865/ GU539866/ GU539867/ GU539868/ GU539869/ GU539870/ GU539871/ GU539872/ GU539873/ GU539874/ GU539875/ GU539876/ GU539877/ GU539878/ GU539879/ GU539880/ GU539881/ GU539882/ GU539883/ GU539884/ GU539885/ GU539886/ GU539887/ GU539888/ GU539889/ GU539890/ GU539891/ GU539892/ GU539893/ GU539894/ GU539895/ GU539896/ GU539897/ GU539898/ GU539899/ GU539900/ GU539901/ GU539902/ GU539903/ GU539904/ GU539905/ GU539906/ GU539907/ GU539908/ GU539909/ GU539910/ GU539911/ GU539912/ GU539913/ GU539914/ GU539915/ GU539916/ GU539917/ GU539918/ GU539919/ GU539920/ GU539921/ GU539922/ GU539923/ GU539924/ GU539925/ GU539926/ GU539927/ GU539928/ GU539929/ GU539930/ GU539931/ GU539932/ GU539933/ GU539934/ GU539935/ GU539936/ GU539937/ GU539938/ GU539939/ GU539940/ GU539941/ GU539942/ GU539943/ GU539944/ GU539945/ GU539946/ GU539947/ GU539948/ GU539949/ GU539950/ GU539951/ GU539952/ GU539953/ GU539954/ GU539955/ GU539956/ GU539957/ GU539958/ GU539959/ GU539960/ GU539961/ GU539962/ GU539963/ GU539964/ GU539965/ GU539966/ GU539967/ GU539968/ GU539969/ GU539970/ GU539971/ GU539972/ GU539973/ GU539974/ GU539975/ GU539976/ GU539977/ GU539978/ GU539979/ GU539980/ GU539981/ GU539982/ GU539983/ GU539984/ GU539985/ GU539986/ GU539987/ GU539988/ GU539989/ GU539990/ GU539991/ GU539992/ GU539993/ GU539994/ GU539995/ GU539996/ GU539997/ GU539998/ GU539999/ GU540000/ GU540001/ GU540002/ GU540003/ GU540004/ GU540005/ GU540006/ GU540007/ GU540008/ GU540009/ GU540010/ GU540011/ GU540012/ GU540013/ GU540014/ GU540015/ GU540016/ GU540017/ GU540018/ GU540019/ GU540020/ GU540021/ GU540022/ GU540023/ GU540024/ GU540025/ GU540026/ GU540027/ GU540028/ GU540029/ GU540030/ GU540031/ GU540032/ GU540033/ GU540034/ GU540035/ GU540036/ GU540037/ GU540038/ GU540039/ GU540040/ GU540041/ GU540042/ GU540043/ GU540044/ GU540045/ GU540046/ GU540047/ GU540048/ GU540049/ GU540050/ GU540051/ GU540052/ GU540053/ GU540054/ GU540055/ GU540056/ GU540057/ GU540058/ GU540059/ GU540060/ GU540061/ GU540062/ GU540063/ GU540064/ GU540065/ GU540066/ GU540067/ GU540068/ GU540069/ GU540070/ GU540071/ GU540072/ GU540073/ GU540074/ GU540075/ GU540076/ GU540077/ GU540078/ GU540079/ GU540080/ GU540081/ GU540082/ GU540083/ GU540084/ GU540085/ GU540086/ GU540087/ GU540088/ GU540089/ GU540090/ GU540091/ GU540092/ GU540093/ GU540094/ GU540095/ GU540096/ GU540097/ GU540098/ GU540099/ GU540100/ GU540101/ GU540102/ GU540103/ GU540104/ GU540105/ GU540106/ GU540107/ GU540108/ GU540109/ GU540110/ GU540111/ GU540112/ GU540113/ GU540114/ GU540115/ GU540116/ GU540117/ GU540118/ GU540119/ GU540120/ GU540121/ GU540122/ GU540123/ GU540124/ GU540125/ GU540126/ GU540127/ GU540128/ GU540129/ GU540130/ GU540131/ GU540132/ GU540133/ GU540134/ GU540135/ GU540136/ GU540137/ GU540138/ GU540139/ GU540140/ GU540141/ GU540142/ GU540143/ GU540144/ GU540145/ GU540146/ GU540147/ GU540148/ GU540149/ GU540150/ GU540151/ GU540152/ GU540153/ GU540154/ GU540155/ GU540156/ GU540157/ GU540158/ GU540159/ GU540160/ GU540161/ GU540162/ GU540163/ GU540164/ GU540165/ GU540166/ GU540167/ GU540168/ GU540169/ GU540170/ GU540171/ GU540172/ GU540173/ GU540174/ GU540175/ GU540176/ GU540177/ GU540178/ GU540179/ GU540180/ GU540181/ GU540182/ GU540183/ GU540184/ GU540185/ GU540186/ GU540187/ GU540188/ GU540189/ GU540190/ GU540191/ GU540192/ GU540193/ GU540194/ GU540195/ GU540196/ GU540197/ GU540198/ GU540199/ GU540200/ GU540201/ GU540202/ GU540203/ GU540204/ GU540205/ GU540206/ GU540207/ GU540208/ GU540209/ GU540210/ GU540211/ GU540212/ GU540213/ GU540214/ GU540215/ GU540216/ GU540217/ GU540218/ GU540219/ GU540220/ GU540221/ GU540222/ GU540223/ GU540224/ GU540225/ GU540226/ GU540227/ GU540228/ GU540229/ GU540230/ GU540231/ GU540232/ GU540233/ GU540234/ GU540235/ GU540236/ GU540237/ GU540238/ GU540239/ GU540240/ GU540241/ GU540242/ GU540243/ GU540244/ GU540245/ GU540246/ GU540247/ GU540248/ GU540249/ GU540250/ GU540251/ GU540252/ GU540253/ GU540254/ GU540255/ GU540256/ GU540257/ GU540258/ GU540259/ GU540260/ GU540261/ GU540262/ GU540263/ GU540264/ GU540265/ GU540266/ GU540267/ GU540268/ GU540269/ GU540270/ GU540271/ GU540272/ GU540273/ GU540274/ GU540275/ GU540276/ GU540277/ GU540278/ GU540279/ GU540280/ GU540281/ GU540282/ GU540283/ GU540284/ GU540285/ GU540286/ GU540287/ GU540288/ GU540289/ GU540290/ GU540291/ GU540292/ GU540293/ GU540294/ GU540295/ GU540296/ GU540297/ GU540298/ GU540299/ GU540300/ GU540301/ GU540302/ GU540303/ GU540304/ GU540305/ GU540306/ GU540307/ GU540308/ GU540309/ GU540310/ GU540311/ GU540312/ GU540313/ GU540314/ GU540315/ GU540316/ GU540317/ GU540318/ GU540319/ GU540320/ GU540321/ GU540322/ GU540323/ GU540324/ GU540325/ GU540326/ GU540327/ GU540328/ GU540329/ GU540330/ GU540331/ GU540332/ GU540333/ GU540334/ GU540335/ GU540336/ GU540337/ GU540338/ GU540339/ GU540340/ GU540341/ GU540342/ GU540343/ GU540344/ GU540345/ GU540346/ GU540347/ GU540348/ GU540349/ GU540350/ GU540351/ GU540352/ GU540353/ GU540354/ GU540355/ GU540356/ GU540357/ GU540358/ GU540359/ GU540360/ GU540361/ GU540362/ GU540363/ GU540364/ GU540365/ GU540366/ GU540367/ GU540368/ GU540369/ GU540370/ GU540371/ GU540372/ GU540373/ GU540374/ GU540375/ GU540376/ GU540377/ GU540378/ GU540379/ GU540380/ GU540381/ GU540382/ GU540383/ GU540384/ GU540385/ GU540386/ GU540387/ GU540388/ GU540389/ GU540390/ GU540391
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; 0 / Sewage
  •  go-up   go-down


24. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P: Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res; 2005 Oct 15;11(20):7480-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To identify markers that predict response to EGFR-based chemotherapy regimens, we analyzed the response of human colorectal cancer cell lines to the EGFR-tyrosine kinase inhibitor, gefitinib (Iressa, AstraZeneca, Wilmington, DE), as a single agent and in combination with oxaliplatin and 5-fluorouracil (5-FU).
  • EXPERIMENTAL DESIGN: Cell viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and crystal violet cell viability assays and analyzed by ANOVA.
  • RESULTS: Cell lines displaying high constitutive EGFR phosphorylation (a surrogate marker for EGFR activity) were more sensitive to gefitinib.
  • Furthermore, in cell lines exhibiting low constitutive EGFR phosphorylation, an antagonistic interaction between gefitinib and oxaliplatin was observed, whereas in cell lines with high basal EGFR phosphorylation, the interaction was synergistic.
  • In addition, oxaliplatin treatment increased EGFR phosphorylation in those cell lines in which oxaliplatin and gefitinib were synergistic but down-regulated EGFR phosphorylation in those lines in which oxaliplatin and gefitinib were antagonistic.
  • In contrast to oxaliplatin, 5-FU treatment increased EGFR phosphorylation in all cell lines and this correlated with synergistic decreases in cell viability when 5-FU was combined with gefitinib.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Dose-Response Relationship, Drug. Drug Antagonism. Fluorouracil / pharmacology. Gene Expression / drug effects. Humans. Organoplatinum Compounds / pharmacology. Phosphorylation / drug effects. Protein Kinase Inhibitors / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243822.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / RNA, Messenger; 04ZR38536J / oxaliplatin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Stacey SN, Gudbjartsson DF, Sulem P, Bergthorsson JT, Kumar R, Thorleifsson G, Sigurdsson A, Jakobsdottir M, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Scherer D, Rudnai P, Gurzau E, Koppova K, Höiom V, Botella-Estrada R, Soriano V, Juberías P, Grasa M, Carapeto FJ, Tabuenca P, Gilaberte Y, Gudmundsson J, Thorlacius S, Helgason A, Thorlacius T, Jonasdottir A, Blondal T, Gudjonsson SA, Jonsson GF, Saemundsdottir J, Kristjansson K, Bjornsdottir G, Sveinsdottir SG, Mouy M, Geller F, Nagore E, Mayordomo JI, Hansson J, Rafnar T, Kong A, Olafsson JH, Thorsteinsdottir U, Stefansson K: Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet; 2008 Nov;40(11):1313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits.
  • To search for new sequence variants that confer risk of cutaneous basal cell carcinoma (BCC), we conducted a genome-wide SNP association study of 930 Icelanders with BCC and 33,117 controls.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Chromosomes, Human, Pair 1 / genetics. Genetic Predisposition to Disease. Melanoma / genetics. Mutation / genetics. Pigmentation / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adipose Tissue / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Aging. Alleles. Carcinoma, Squamous Cell / genetics. Chromosomal Proteins, Non-Histone / genetics. Chromosomal Proteins, Non-Histone / metabolism. Guanine Nucleotide Exchange Factors / genetics. Guanine Nucleotide Exchange Factors / metabolism. Humans. Middle Aged. Models, Genetic. Polymorphism, Single Nucleotide / genetics. Quantitative Trait, Heritable. RNA / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18849993.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Guanine Nucleotide Exchange Factors; 0 / RCC2 protein, human; 63231-63-0 / RNA
  •  go-up   go-down


26. Barr RK, Lynn HE, Moretti PA, Khew-Goodall Y, Pitson SM: Deactivation of sphingosine kinase 1 by protein phosphatase 2A. J Biol Chem; 2008 Dec 12;283(50):34994-5002
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell exposure to a wide array of growth factors, cytokines, and other cell agonists can result in a rapid and transient increase in SK activity via an activating phosphorylation.
  • Finally, both basal and tumor necrosis factor-alpha-stimulated cellular SK1 activity were regulated by molecular manipulation of PP2Ac activity.
  • [MeSH-minor] Animals. Enzyme Activation. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Silencing. Glutathione Transferase / metabolism. Humans. Muscle, Skeletal / enzymology. Phosphorylation. Protein Structure, Tertiary. Rabbits. Serine / chemistry. Subcellular Fractions / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2000 Sep 1;350 Pt 2:429-41 [10947957.001]
  • [Cites] Front Biosci. 1998 Dec 15;3:D1262-73 [9851914.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):417-39 [11171037.001]
  • [Cites] Cancer Lett. 2001 Sep 10;170(1):1-13 [11448528.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6391-8 [11698396.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):7996-8003 [11777919.001]
  • [Cites] Virology. 2001 Nov 25;290(2):192-8 [11883184.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2111-23 [11884599.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4221-6 [11904383.001]
  • [Cites] Science. 2002 Apr 12;296(5566):346-9 [11923495.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21453-7 [11967257.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22847-52 [11929874.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1596-602 [12200669.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49545-53 [12393916.001]
  • [Cites] Br J Pharmacol. 2003 Apr;138(7):1303-12 [12711631.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5962-9 [14522923.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5491-500 [14532121.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1885-9 [14534713.001]
  • [Cites] FEBS Lett. 2003 Nov 6;554(1-2):189-93 [14596938.001]
  • [Cites] Am J Obstet Gynecol. 2003 Dec;189(6):1666-9 [14710095.001]
  • [Cites] Eur J Biochem. 1985 Jun 3;149(2):305-13 [2986974.001]
  • [Cites] Nature. 1991 Sep 12;353(6340):170-3 [1716348.001]
  • [Cites] EMBO J. 1993 Mar;12(3):987-96 [8384557.001]
  • [Cites] J Biol Chem. 1993 Jul 25;268(21):15523-30 [8393446.001]
  • [Cites] Physiol Rev. 1993 Oct;73(4):673-99 [8415923.001]
  • [Cites] J Cell Sci. 1994 Sep;107 ( Pt 9):2609-16 [7844174.001]
  • [Cites] Mol Biol Cell. 1995 Jan;6(1):119-34 [7749193.001]
  • [Cites] Semin Cancer Biol. 1995 Aug;6(4):229-37 [8541518.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):800-3 [8657285.001]
  • [Cites] J Biol Chem. 1998 Jan 16;273(3):1357-64 [9430669.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20296-300 [10400650.001]
  • [Cites] J Virol. 1999 Sep;73(9):7390-8 [10438829.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47732-9 [15364932.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49551-61 [15364934.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):49-54 [15623571.001]
  • [Cites] FEBS Lett. 2005 Jun 13;579(15):3278-86 [15913612.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36865-72 [16093248.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11667-75 [16357178.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):43030-8 [16243846.001]
  • [Cites] J Obstet Gynaecol. 2006 Jan;26(1):37-41 [16390708.001]
  • [Cites] FASEB J. 2006 Feb;20(2):386-8 [16319132.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):11693-701 [16522638.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34499-505 [10567432.001]
  • [Cites] J Lipid Res. 2006 Jun;47(6):1128-39 [16520486.001]
  • [Cites] J Biol Chem. 2006 Jul 7;281(27):18859-67 [16679323.001]
  • [Cites] IUBMB Life. 2006 Aug;58(8):467-72 [16916784.001]
  • [Cites] J Biol Chem. 2006 Oct 13;281(41):30503-11 [16895907.001]
  • [Cites] Cell Mol Life Sci. 2006 Dec;63(24):2979-91 [17072501.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2408-21 [17717597.001]
  • [Cites] Cancer Lett. 2008 Jan 18;259(1):28-38 [17977648.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50 [18216770.001]
  • [Cites] Arch Biochem Biophys. 1998 Jul 15;355(2):197-200 [9675027.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33561-5 [9837938.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33945-50 [10944534.001]
  • (PMID = 18852266.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 452VLY9402 / Serine; EC 2.5.1.18 / Glutathione Transferase; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / sphingosine kinase; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.3.16 / Protein Phosphatase 2
  • [Other-IDs] NLM/ PMC3259904
  •  go-up   go-down


27. Liu Y, Nie H, Bansil R, Steinhart M, Bang J, Lodge TP: Kinetics of disorder-to-fcc phase transition via an intermediate bcc state. Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Jun;73(6 Pt 1):061803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of disorder-to-fcc phase transition via an intermediate bcc state.
  • Time-resolved small-angle x-ray scattering measurements reveal that a long-lived intermediate bcc state forms when a poly(styrene-b-isoprene) diblock copolymer solution in an isoprene selective solvent is rapidly cooled from the disordered micellar fluid at high temperature to an equilibrium fcc state.
  • The kinetics of the epitaxial growth of the [111] fcc peak from the [110] bcc peak was obtained by fitting the scattering data to a simple model of the transformation.
  • The growth of the [111] fcc peak agrees with the Avrami model of nucleation and growth kinetics with an exponent n=1.4, as does the initial decay of the [110] bcc peak, with an exponent n=1.3.
  • The data were also found to be in good agreement with the Cahn model of grain boundary nucleation and growth.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906856.001).
  • [ISSN] 1539-3755
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Saal LH, Gruvberger-Saal SK, Persson C, Lövgren K, Jumppanen M, Staaf J, Jönsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A: Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet; 2008 Jan;40(1):102-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.
  • Basal-like breast cancer (BBC) is a subtype of breast cancer with poor prognosis.
  • Here we show that heterozygous inactivation of the tumor suppressor gene Pten leads to the formation of basal-like mammary tumors in mice, and that loss of PTEN expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary breast cancers.


29. Broers S, Smets E, Bindels P, Evertsz' FB, Calff M, de Haes H: Training general practitioners in behavior change counseling to improve asthma medication adherence. Patient Educ Couns; 2005 Sep;58(3):279-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Training general practitioners in behavior change counseling to improve asthma medication adherence.
  • OBJECTIVE: Adherence to asthma medication regimens is problematic in general practice.
  • We developed and evaluated a communication training for general practitioners (GPs) to help them address medication adherence during routine consultations.
  • This paper describes the development of the training and evaluation results of a pilot study.
  • METHODS: The training was based on behavior change counseling (BCC), a technique derived from motivational interviewing.
  • We developed a five phases BCC consultation model.
  • Participating GPs answered questions at baseline (T0), directly after (T1) and 4-10 months after (T2) the training that assessed their attitudes and confidence regarding adherence communication.
  • They completed evaluation forms at T1 and T2.
  • RESULTS: The 19 participating GPs were positive about the course and the feasibility of BCC in GP consultations.
  • Also, after the training, their attitudes and confidence had improved (p<0.05) and all reported to use BCC skills at least sometimes 4-10 months after the training.
  • CONCLUSION: These positive effects provide us with some hope that the training positively influenced the GP's communication behavior.
  • PRACTICE IMPLICATIONS: If further data on physician behavior and patient outcomes justify implementation of the training, it would then be worthwhile to also involve practice nurses.
  • [MeSH-major] Asthma / drug therapy. Counseling / education. Education, Medical, Continuing. Family Practice / education. Patient Compliance
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Netherlands. Pilot Projects. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024211.001).
  • [ISSN] 0738-3991
  • [Journal-full-title] Patient education and counseling
  • [ISO-abbreviation] Patient Educ Couns
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


30. Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, Arbeit JM: Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res; 2010 Apr 15;70(8):3287-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To model gain of function in epithelial malignancy, we targeted Rheb expression to murine basal keratinocytes of transgenic mice at levels similar to those that occur in human squamous cancer cell lines.
  • Rheb-induced tumor persistence and neoplastic molecular alterations were mTORC1 dependent.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] Curr Biol. 2000 Jan 13;10(1):47-50 [10660304.001]
  • [Cites] J Histochem Cytochem. 2009 Jul;57(7):649-63 [19289554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Genes Dev. 2001 Oct 1;15(19):2520-32 [11581158.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):129-40 [11896568.001]
  • [Cites] Cancer Cell. 2004 May;5(5):489-500 [15144956.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):720-8 [15343391.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Nat Med. 2005 Jan;11(1):43-9 [15592573.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):78-84 [16359855.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2512-21 [17041095.001]
  • [Cites] J Urol. 2007 Jan;177(1):346-52 [17162089.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:443-67 [16968213.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):316-23 [17277771.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):209-16 [17276050.001]
  • [Cites] Mol Cell. 2007 Mar 23;25(6):903-15 [17386266.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):667-81 [17600126.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4964-73 [17785546.001]
  • [Cites] Curr Biol. 2008 Jan 8;18(1):56-62 [18164202.001]
  • [Cites] Breast Cancer Res. 2007;9(4):212 [17705880.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1167-71 [18281551.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3343-54 [18199827.001]
  • [Cites] Mol Cell. 2008 Apr 25;30(2):214-26 [18439900.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):799-809 [18471051.001]
  • [Cites] Genes Dev. 2008 Aug 15;22(16):2172-7 [18708577.001]
  • [Cites] Genes Dev. 2008 Aug 15;22(16):2178-88 [18708578.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13544-9 [18768809.001]
  • [Cites] Pathology. 2009 Jan;41(1):40-7 [19089739.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):91-102 [19185844.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):103-13 [19185845.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5 [11504907.001]
  • (PMID = 20388784.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101012-05; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA098258; United States / PHS HHS / / R01-101012; United States / NCI NIH HHS / CA / R01 CA101012; United States / NCI NIH HHS / CA / CA101012-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Multiprotein Complexes; 0 / Neuropeptides; 0 / Proteins; 0 / RHEB protein, human; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS178666; NLM/ PMC2855737
  •  go-up   go-down


31. Angiero F, Farronato G, Dessy E, Magistro S, Seramondi R, Farronato D, Benedicenti S, Tetè S: Evaluation of the cytotoxic and genotoxic effects of orthodontic bonding adhesives upon human gingival papillae through immunohistochemical expression of p53, p63 and p16. Anticancer Res; 2009 Oct;29(10):3983-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In no case were morphological alterations visible by microscopy out of the 69 banded patients; four (5.80%) were positive for p53 and two for p63 expression in the basal and suprabasal layers (2.90%).
  • CONCLUSION: The significance of p53, p63 and p16 positivity, and whether these proteins may serve as biomarkers to predict the risk of developing oral lesions (dysplasia, oral cancer) is still unclear.
  • Although details of the mechanisms leading to cell death, genotoxicity and cell-cycle delay are not fully understood, resin monomers may alter cell function in the oral cavity.
  • [MeSH-major] Dental Cements / toxicity. Gingiva / drug effects. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Mouth Diseases / chemically induced. Mouth Neoplasms / chemically induced. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846940.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Dental Cements; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


32. Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N: Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros; 2010 Jan;9(1):51-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Anti-Bacterial Agents / therapeutic use. Biofilms. Breath Tests. Child. Drug Resistance, Bacterial. Female. Forced Expiratory Volume. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Interferon-gamma / blood. Interferon-gamma / metabolism. Interleukin-10 / metabolism. Interleukin-1beta / metabolism. Interleukin-6 / blood. Interleukin-6 / metabolism. Interleukin-8 / metabolism. Male. Pneumonia, Bacterial / complications. Pneumonia, Bacterial / drug therapy. Pneumonia, Bacterial / immunology. Retrospective Studies. Sputum / metabolism. Sputum / microbiology. Tumor Necrosis Factor-alpha / metabolism. Young Adult

  • Genetic Alliance. consumer health - BabysFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19939747.001).
  • [ISSN] 1873-5010
  • [Journal-full-title] Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • [ISO-abbreviation] J. Cyst. Fibros.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


33. Bossert T, Walther T, Vondrys D, Gummert JF, Kostelka M, Mohr FW: Cardiac fibroma as an inherited manifestation of nevoid basal-cell carcinoma syndrome. Tex Heart Inst J; 2006;33(1):88-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac fibroma as an inherited manifestation of nevoid basal-cell carcinoma syndrome.
  • Echocardiography revealed a left ventricular tumor.
  • The tumor was resected through a left ventriculotomy, and the left ventricle was reconstructed after a partial ventriculectomy Histologic investigation showed a completely resected benign fibroma.
  • The 30-year-old mother was known to have nevoid basal-cell carcinoma syndrome, which can be associated with cardiac fibromas.

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2001 Apr;71(4):1354-6 [11308193.001]
  • [Cites] Ann Thorac Surg. 2003 Apr;75(4):1306-8 [12683582.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Jul;112(7):773-5 [3707741.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Am Heart J. 1997 Dec;134(6):1107-14 [9424072.001]
  • [Cites] Pediatr Cardiol. 1991 Apr;12(2):118-20 [1866331.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):862-70 [7967668.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):382-6 [7779860.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:176-82 [2237899.001]
  • (PMID = 16572881.001).
  • [ISSN] 0730-2347
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1413607
  •  go-up   go-down


34. Raaby L, Otkjær K, Salvskov-Iversen ML, Johansen C, Iversen L: A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis. Dermatol Reports; 2010 Aug 31;2(2):e14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis.
  • 14-3-3 is a highly conserved protein involved in a number of cellular processes including cell signalling, cell cycle regulation and gene transcription.
  • To investigate the expression of the seven 14-3-3 isoforms in involved and uninvolved skin from psoriasis, basal cell carcinoma (BCC), atopic dermatitis and nickel induced allergic contact dermatitis.
  • These results demonstrate a disease specific expression profile of the 14-3-3τ and 14-3-3σ iso-forms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25386251.001).
  • [ISSN] 2036-7392
  • [Journal-full-title] Dermatology reports
  • [ISO-abbreviation] Dermatol Reports
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC4211473
  • [Keywords] NOTNLM ; 14-3-3 proteins / allergic contact dermatitis / atopic dermatitis. / basal cell carcinoma / psoriasis
  •  go-up   go-down


35. Jankovic I, Kovacevic P, Visnjic M, Jankovic D, Binic I, Jankovic A: Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence? An Bras Dermatol; 2010 Nov-Dec;85(6):872-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence?
  • INTRODUCTION: Basal cell carcinoma is the most common tumor of the eyelid.
  • OBJECTIVE: To define the relationship between margin clearance at excision and the recurrence rate of basal cell carcinoma of the eyelid.
  • METHODS: This prospective study was conducted with 111 patients submitted to surgery for basal cell carcinoma of the eyelid between 2001 and 2003 and followed up for a period of five years.
  • The patients were evaluated according to age, tumor site, recurrence rate and margin clearance at excision.
  • RESULTS: No significant association was found between incomplete tumor excision and recurrence except in patients under 56 years of age, female patients and in the case of tumors of the medial canthus.
  • CONCLUSION: A risk of recurrence in incompletely excised basal cell carcinomas of the eyelid was only confirmed in younger patients, females and for tumors of the medial canthus.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Bras Dermatol. 2011 Mar-Apr;86(2):401; author reply 401-3 [21603839.001]
  • (PMID = 21308312.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


36. Ma N, Tagawa T, Hiraku Y, Murata M, Ding X, Kawanishi S: 8-Nitroguanine formation in oral leukoplakia, a premalignant lesion. Nitric Oxide; 2006 Mar;14(2):137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, proliferating cell nuclear antigen and p53 were expressed in 8-nitroguanine-positive epithelial cells in the basal layer.

  • Genetic Alliance. consumer health - Leukoplakia.
  • Genetic Alliance. consumer health - Oral leukoplakia.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16290060.001).
  • [ISSN] 1089-8603
  • [Journal-full-title] Nitric oxide : biology and chemistry
  • [ISO-abbreviation] Nitric Oxide
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 8-nitroguanine; 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 5Z93L87A1R / Guanine; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 1.14.13.39 / Nitric Oxide Synthase Type II; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


37. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol; 2007 Nov 1;25(31):4952-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We estimated the probabilities of death resulting from breast cancer and from other causes, and analyzed associations of patient and tumor characteristics with OS, BCSM, and non-breast cancer-related mortality using the log-rank test, Cox proportional hazards models, and a competing-risk model.
  • Characteristics associated with increased probability of BCSM included age younger than 50 years at diagnosis, high tumor grade, estrogen receptor-negative status, progesterone receptor-negative status, and fewer than six nodes removed at axillary dissection.
  • [MeSH-major] Breast Neoplasms / mortality. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. SEER Program. Survival Analysis. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Kohno H, Suzuki R, Yasui Y, Miyamoto S, Wakabayashi K, Tanaka T: Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin Cancer Res; 2007 Apr 15;13(8):2519-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the current study, we investigated whether ursodeoxycholic acid (UDCA) can inhibit colitis-related mouse colon carcinogenesis and compared it with the effects of sulfasalazine.
  • They are then maintained on a basal diet mixed with UDCA (0.016%, 0.08%, or 0.4%) or sulfasalazine (0.05%) for 17 weeks.
  • At week 20, the tumor-inhibitory effects of both chemicals were assessed by counting the incidence and multiplicity of colonic neoplasms.
  • The immunohistochemical expression of the proliferating cell nuclear antigen labeling index in colonic epithelial malignancies was also assessed.
  • Finally, at week 5, the mRNA expressions for cyclooxygenase-2, inducible nitric oxide synthase, peroxisome proliferator-activated receptor-gamma, and tumor necrosis factor-alpha were measured in nontumorous mucosa.
  • The treatment also significantly lowered the proliferating cell nuclear antigen labeling index in the colonic malignancies.
  • UDCA feeding reduced the expression of inducible nitric oxide synthase and tumor necrosis factor-alpha mRNA in the colonic mucosa, while not significantly affecting the expression of cyclooxygenase-2 mRNA and peroxisome proliferator-activated receptor-gamma mRNA.
  • Sulfasalazine caused a nonsignificant reduction in the incidence and multiplicity of colonic neoplasia and did not affect these mRNA expression.
  • [MeSH-major] Colitis / complications. Colonic Neoplasms / etiology. Colonic Neoplasms / prevention & control. Sulfasalazine / therapeutic use. Ursodeoxycholic Acid / therapeutic use
  • [MeSH-minor] Animals. Anticarcinogenic Agents. Azoxymethane / toxicity. Cyclooxygenase 2 / genetics. Disease Models, Animal. Male. Mice. Mice, Inbred ICR. RNA, Messenger / genetics

  • Hazardous Substances Data Bank. SULFASALAZINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438113.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / RNA, Messenger; 3XC8GUZ6CB / Sulfasalazine; 724L30Y2QR / Ursodeoxycholic Acid; EC 1.14.99.1 / Cyclooxygenase 2; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


39. Shen A, Chen M, Niu S, Sun L, Gao S, Shi S, Li X, Lv Q, Guo Z, Cheng C: Changes in mRNA for CAPON and Dexras1 in adult rat following sciatic nerve transection. J Chem Neuroanat; 2008 Jan;35(1):85-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carboxy-terminal post synaptic density protein/Drosophila disc large tumor suppressor/zonula occuldens-1 protein (PDZ) ligand of neuronal nitric oxide synthase (CAPON), as an adaptor, interacts with nNOS via the PDZ domain helping regulate nNOS activity at postsynaptic sites in neurons.
  • Signals of mRNA for CAPON and Dexras1 were initially expressed in these neural tissues mentioned, transiently increased at certain time periods after sciatic axotomy and finally recovered to the basal level.
  • [MeSH-minor] Animals. Axotomy. Cell Survival / genetics. Female. Ganglia, Spinal / metabolism. Ganglia, Spinal / pathology. Ganglia, Spinal / physiopathology. Gene Expression Regulation, Enzymologic / genetics. In Situ Hybridization. Macromolecular Substances / metabolism. Male. Nerve Regeneration / genetics. Posterior Horn Cells / metabolism. Posterior Horn Cells / pathology. Posterior Horn Cells / physiopathology. RNA, Messenger / analysis. RNA, Messenger / metabolism. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction. Spinal Nerve Roots / metabolism. Spinal Nerve Roots / pathology. Wallerian Degeneration / genetics. Wallerian Degeneration / metabolism. Wallerian Degeneration / physiopathology

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768032.001).
  • [ISSN] 0891-0618
  • [Journal-full-title] Journal of chemical neuroanatomy
  • [ISO-abbreviation] J. Chem. Neuroanat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Dexras1 protein, rat; 0 / Macromolecular Substances; 0 / NOS1AP protein, rat; 0 / RNA, Messenger; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type I; EC 3.6.1.- / Rasd1 protein, mouse; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


40. LeHoux JG, Lefebvre A: Novel protein kinase C-epsilon inhibits human CYP11B2 gene expression through ERK1/2 signalling pathway and JunB. J Mol Endocrinol; 2006 Feb;36(1):51-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of wild-type ERK1 and ERK2 significantly reduced basal as well as Ang II-stimulated human -2023CYP11B2-CAT activity; conversely, the two dominant negative mutants increased them.
  • [MeSH-minor] Base Sequence. Blotting, Western. Cell Line, Tumor. Chloramphenicol O-Acetyltransferase / genetics. DNA Primers. Humans. Promoter Regions, Genetic. Protein Kinase Inhibitors / pharmacology. RNA, Messenger / genetics. Transcription, Genetic / drug effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16461926.001).
  • [ISSN] 0952-5041
  • [Journal-full-title] Journal of molecular endocrinology
  • [ISO-abbreviation] J. Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-jun; 0 / RNA, Messenger; EC 1.14.15.4 / Cytochrome P-450 CYP11B2; EC 2.3.1.28 / Chloramphenicol O-Acetyltransferase; EC 2.7.11.13 / Protein Kinase C-epsilon; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


41. Baptiste-Okoh N, Barsotti AM, Prives C: Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner. Cell Cycle; 2008 May 1;7(9):1133-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upon treatment with some DNA damaging agents, human H1299 tumor-derived cells expressing inducible versions of wild-type or mutant p53 with inactive transactivation domain I (p53(Q22/S23)) undergo apoptosis.
  • In cells expressing either version of p53, caspase 2 activation is required for release of cytochrome c and cell death.
  • Despite the finding that caspase 2 is essential for DNA damage-facilitated, p53-mediated apoptosis, induction of wild-type p53 (with or without DNA damage) resulted in a reduction of caspase 2 mRNA and protein levels.
  • Deletion of p21 or E2F-1 not only abrogated repression of caspase 2, but also stimulated the expression of caspase 2 above basal levels, implicating the requirement for an intact p21/Rb/E2F pathway in the downregulation of caspase 2.
  • Downregulation of caspase 2 levels by p53 may help to determine cell fate by preventing cell death when unnecessary.
  • [MeSH-major] Apoptosis / physiology. Caspase 2 / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cysteine Endopeptidases / metabolism. Down-Regulation / physiology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Binding Sites / physiology. Cell Death / physiology. Cell Line. Cell Lineage / physiology. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. E2F1 Transcription Factor / genetics. E2F1 Transcription Factor / metabolism. Humans. Protein Structure, Tertiary / physiology. Retinoblastoma Protein / genetics. Retinoblastoma Protein / metabolism. Signal Transduction / drug effects. Signal Transduction / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418048.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / E2F1 Transcription Factor; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / CASP2 protein, human; EC 3.4.22.- / Caspase 2; EC 3.4.22.- / Cysteine Endopeptidases
  •  go-up   go-down


42. Akan B, Böhmig G, Sunder-Plassmann G, Borchhardt KA: Prevalence of hypercalcitoninemia in patients on maintenance dialysis referred to kidney transplantation. Clin Nephrol; 2009 May;71(5):538-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Elevated calcitonin concentrations in dialysis patients had led to thyroidectomy for a benign C-cell hyperplasia in dozens of patients in the past decade.
  • All patients with basal calcitonin concentrations above 50 pg/ml were men (highest calcitonin concentration was 290 pg/ml).
  • Two of them underwent thyroidectomy and had C-cell hyperplasia.
  • [MeSH-major] Biomarkers, Tumor / blood. Calcitonin / blood. Carcinoma, Medullary / epidemiology. Kidney Failure, Chronic / therapy. Kidney Transplantation. Renal Dialysis / methods. Thyroid Neoplasms / epidemiology


43. Markel TA, Wang M, Crisostomo PR, Manukyan MC, Poynter JA, Meldrum DR: Neonatal stem cells exhibit specific characteristics in function, proliferation, and cellular signaling that distinguish them from their adult counterparts. Am J Physiol Regul Integr Comp Physiol; 2008 May;294(5):R1491-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Growth factors were measured via ELISA, proliferation via daily cell counts, cell surface markers via flow cytometry, and pluripotent potential via alkaline phosphatase activity. nBMSCs produced lower levels of IL-6 and VEGF, but higher levels of IGF-1 under basal conditions, as well as after stimulation with TNF, but not LPS.
  • Neonatal and adult BMSCs had similar pluripotent potentials and cell surface markers, but nBMSCs proliferated faster.
  • [MeSH-minor] Animals. Bone Marrow Cells / physiology. Cell Proliferation. Enzyme-Linked Immunosorbent Assay. Extracellular Signal-Regulated MAP Kinases / metabolism. Flow Cytometry. Insulin-Like Growth Factor I / biosynthesis. Interleukin-6 / biosynthesis. Male. Membrane Proteins / metabolism. Mice. Mice, Inbred C57BL. Tumor Necrosis Factors / metabolism. Vascular Endothelial Growth Factor A / biosynthesis. p38 Mitogen-Activated Protein Kinases / biosynthesis

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18385461.001).
  • [ISSN] 0363-6119
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / F32 HL 085982; United States / NHLBI NIH HHS / HL / K99/R00 HL 0876077-0; United States / NIGMS NIH HHS / GM / R01 GM 070628; United States / NHLBI NIH HHS / HL / R01 HL 085595
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Membrane Proteins; 0 / Tumor Necrosis Factors; 0 / Vascular Endothelial Growth Factor A; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


44. Calin-Jageman IE, Wang J, Bannon MJ: Regulation of the preprotachykinin-I gene promoter through a protein kinase A-dependent, cyclic AMP response element-binding protein-independent mechanism. J Neurochem; 2006 Apr;97(1):255-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that the activation protein 1/cAMP response element (AP1/CRE) site centered at -196 relative to the transcription start site was important for basal and forskolin-induced PPT promoter activity.
  • CREB-A) did not affect basal or forskolin-induced PPT promoter activity.
  • [MeSH-minor] Animals. Cell Line, Tumor. Colforsin / pharmacology. Conserved Sequence. DNA-Binding Proteins / genetics. Enzyme Inhibitors / pharmacology. Evolution, Molecular. Genes, Reporter / physiology. Molecular Sequence Data. Protein Binding / genetics. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Rats. Sequence Homology, Nucleic Acid. Transcription Factor AP-1 / genetics. Transcriptional Activation / drug effects. Transcriptional Activation / physiology. Up-Regulation / drug effects. Up-Regulation / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515544.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS34935
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein; 0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / Protein Precursors; 0 / RNA, Messenger; 0 / Tachykinins; 0 / Transcription Factor AP-1; 0 / preprotachykinin; 1F7A44V6OU / Colforsin; E0399OZS9N / Cyclic AMP; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  •  go-up   go-down


45. Guldner L, Multigner L, Héraud F, Monfort C, Thomé JP, Giusti A, Kadhel P, Cordier S: Pesticide exposure of pregnant women in Guadeloupe: ability of a food frequency questionnaire to estimate blood concentration of chlordecone. Environ Res; 2010 Feb;110(2):146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pesticide exposure of pregnant women in Guadeloupe: ability of a food frequency questionnaire to estimate blood concentration of chlordecone.
  • CONTEXT: Chlordecone, an environmentally persistent organochlorine insecticide used intensively in banana culture in the French West Indies until 1993, has permanently polluted soils and contaminated foodstuffs.
  • Consumption of contaminated food is the main source of exposure nowadays.
  • We sought to identify main contributors to blood chlordecone concentration (BCC) and to validate an exposure indicator based on food intakes.
  • MATERIAL AND METHODS: We used a food frequency questionnaire (FFQ) completed by a sample of 194 pregnant women to estimate their dietary exposure to chlordecone and compared it to blood levels.
  • In a first approach, chlordecone daily intake was estimated as the product of daily eaten quantity of 214 foodstuffs, multiplied by their chlordecone content, and summed over all items.
  • We then predicted individual blood chlordecone concentration with empirical weight regression models based on frequency of food consumption, and without contamination data.
  • RESULTS: Among the 191 subjects who had BCC determination, 146 (76%) had detectable values and mean BCC was 0.86 ng/mL (range < LOD-13.2).
  • Mean per capita dietary intake of chlordecone was estimated at 3.3 microg/day (range: 0.1-22.2).
  • Blood chlordecone levels were significantly correlated with food exposure predicted from the empirical weight models (r=0.47, p<0.0001) and, to a lesser extent, with chlordecone intake estimated from food consumption and food contamination data (r=0.20, p=0.007).
  • Main contributors to chlordecone exposure included seafood, root vegetables, and Cucurbitaceous.
  • CONCLUSION: These results show that the Timoun FFQ provides valid estimates of chlordecone exposure.
  • Estimates from empirical weight models correlated better with blood levels of chlordecone than did estimates from the dietary intake assessment.
  • [MeSH-major] Chlordecone / blood. Food Contamination. Pesticides / blood. Pregnancy / blood. Soil Pollutants / blood
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Diet. Environmental Exposure. Female. Guadeloupe. Humans. Middle Aged. Prospective Studies. Regression Analysis. Socioeconomic Factors. Surveys and Questionnaires. Young Adult

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. KEPONE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20003965.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pesticides; 0 / Soil Pollutants; RG5XJ88UDF / Chlordecone
  •  go-up   go-down


46. Bäckvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F: Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res; 2005 Apr 1;571(1-2):65-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma.
  • Detectable lesions occur early during tumor progression, facilitating molecular analysis of the cell populations from both preneoplastic and neoplastic lesions.
  • Alterations of the p53 tumor suppressor gene are very common in non-melanoma skin cancer, and dysregulation of p53 pathways appear to be an early event in the tumor development.
  • The abundance of clones containing p53 mutated keratinocytes adjacent to basal cell (BCC) and squamous cell carcinoma (SCC) suggests a role in human skin carcinogenesis.
  • Here, we present examples of using well-defined cell populations, including single cells, from complex tissue in combination with molecular tools to reveal features involved in skin carcinogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Genetic Heterogeneity. Skin Neoplasms / genetics
  • [MeSH-minor] Humans. Neoplasms, Radiation-Induced / genetics. Ultraviolet Rays


47. Mogensen M, Joergensen TM, Nürnberg BM, Morsy HA, Thomsen JB, Thrane L, Jemec GB: Assessment of optical coherence tomography imaging in the diagnosis of non-melanoma skin cancer and benign lesions versus normal skin: observer-blinded evaluation by dermatologists and pathologists. Dermatol Surg; 2009 Jun;35(6):965-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of optical coherence tomography imaging in the diagnosis of non-melanoma skin cancer and benign lesions versus normal skin: observer-blinded evaluation by dermatologists and pathologists.
  • OBJECTIVES: To describe OCT features in NMSC such as actinic keratosis (AK) and basal cell carcinoma (BCC) and in benign lesions and to assess the diagnostic accuracy of OCT in differentiating NMSC from benign lesions and normal skin.
  • Observer-blinded evaluation of OCT images from 64 BCCs, 1 baso-squamous carcinoma, 39 AKs, two malignant melanomas, nine benign lesions, and 105 OCT images from perilesional skin was performed; 50 OCT images of NMSC and 50 PS-OCT images of normal skin were evaluated twice.
  • OCT diagnosis is less accurate than clinical diagnosis, but high accuracy in distinguishing lesions from normal skin, crucial for delineating tumor borders, was obtained.
  • [MeSH-major] Skin / pathology. Skin Neoplasms / diagnosis. Tomography, Optical Coherence / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19397661.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Kassardjian A, Dakroub Z, Zein OE, Kreydiyyeh SI: Signaling pathway underlying the up-regulatory effect of TNF-alpha on the Na(+)/K(+) ATPase in HepG2 cells. Cytokine; 2010 Mar;49(3):312-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activity of the Na(+)/K(+) ATPase was shown to be reduced during apoptosis and enhanced during cell proliferation.
  • This work investigated whether TNF-alpha exerts also opposite effects on the Na(+)/K(+) ATPase in HepG2 cells and whether these effects are time-dependent.
  • TNF-alpha was shown to exert a stimulatory effect on cJNK and NF-kappaB and an inhibitory effect on caspases which, in the basal state, down-regulate the ATPase.
  • [MeSH-major] Signal Transduction / physiology. Sodium-Potassium-Exchanging ATPase / metabolism. Tumor Necrosis Factor-alpha / physiology. Up-Regulation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20036143.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Caspase Inhibitors; 0 / Cysteine Proteinase Inhibitors; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspases; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


49. Soulairol R, Fu CC, Barreteau C: Structure and magnetism of bulk Fe and Cr: from plane waves to LCAO methods. J Phys Condens Matter; 2010 Jul 28;22(29):295502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structure and magnetism of bulk Fe and Cr: from plane waves to LCAO methods.
  • Magnetic, structural and energetic properties of bulk Fe and Cr were studied using first-principles calculations within density functional theory (DFT).
  • We aimed to identify the dependence of these properties on key approximations of DFT, namely the exchange-correlation functional, the pseudopotential and the basis set.
  • We found a smaller effect of pseudopotentials (PPs) on Fe than on Cr.
  • For instance, the local magnetism of Cr was shown to be particularly sensitive to the potentials representing the core electrons, i.e. projector augmented wave and Vanderbilt ultrasoft PPs predict similar results, whereas standard norm-conserving PPs tend to overestimate the local magnetic moments of Cr in bcc Cr and in dilute bcc FeCr alloys.
  • This drawback is suggested to be closely correlated to the overestimation of Cr solution energy in the latter system.
  • On the other hand, we point out that DFT methods with very reduced localized basis sets (LCAO: linear combination of atomic orbitals) give satisfactory results compared with more robust plane-wave approaches.
  • A minimal-basis representation of '3d' electrons comes to be sufficient to describe non-trivial magnetic phases including spin spirals in both fcc Fe and bcc Cr, as well as the experimental magnetic ground state of bcc Cr showing a spin density wave (SDW) state.
  • In addition, a magnetic 'spd' tight binding model within the Stoner formalism was proposed and validated for Fe and Cr.
  • The respective Stoner parameters were obtained by fitting to DFT data.
  • This efficient semiempirical approach was shown to be accurate enough for studying various collinear and non-collinear phases of bulk Fe and Cr.
  • It also enabled a detailed investigation of different polarization states of SDW in bcc Cr, where the longitudinal state was suggested to be the ground state, consistent with existing experimental data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21399309.001).
  • [ISSN] 1361-648X
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


50. de Longueville F, Lacroix M, Barbuto AM, Bertholet V, Gallo D, Larsimont D, Marcq L, Zammatteo N, Boffe S, Leclercq G, Remacle J: Molecular characterization of breast cancer cell lines by a low-density microarray. Int J Oncol; 2005 Oct;27(4):881-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of breast cancer cell lines by a low-density microarray.
  • We designed a low-density microarray carrying 132 DNA capture sequences highly specific for genes known to be differentially expressed among breast tumors and BCC lines or associated with specific tumor properties (cell-cycle alteration, proteolysis, adhesion, hormone sensitivity, etc).
  • Some data obtained were verified or extended by real-time polymerase chain reaction (real-time PCR), Northern blotting, Western blotting, immunohistochemistry and cell growth studies.
  • A few genes that are highly and specifically expressed in one cell line were identified, such as MGB1 (mammaglobin 1) in Evsa-T cells, and PIP (prolactin-inducible protein) in MDA-MB-453 BCC, suggesting an apocrine origin for these latter cells.
  • In conclusion, our results support the utility of a low-density microarray approach in cases where the cost and exhaustiveness of high-density microarrays may constitute a drawback; for instance, in obtaining a rapid phenotype evaluation in cell populations freshly isolated from breast tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Biotinylation. Blotting, Northern. Blotting, Western. Cell Adhesion. Cell Line, Tumor. Cell Proliferation. Cluster Analysis. DNA, Complementary / metabolism. Estrogen Receptor alpha / metabolism. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Mammaglobin A. Neoplasm Proteins / metabolism. Nucleic Acid Hybridization. Phenotype. Polymerase Chain Reaction. RNA / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Uteroglobin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142302.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Estrogen Receptor alpha; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


51. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM: Gene expression patterns associated with p53 status in breast cancer. BMC Cancer; 2006 Dec 06;6:276
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the tumor suppressor p53 occur more frequently in estrogen receptor (ER) negative, basal-like and HER2-amplified tumors than in luminal, ER positive tumors.
  • The relation between p53 status and subtype can be better studied by combining data from primary tumors with data from isogenic cell line pairs (with and without p53 function).
  • METHODS: The p53-dependent gene expression signatures of four cell lines (MCF-7, ZR-75-1, and two immortalized human mammary epithelial cell lines) were identified by comparing p53-RNAi transduced cell lines to their parent cell lines.
  • Cell lines were treated with vehicle only or doxorubicin to identify p53 responses in both non-induced and induced states.
  • The cell line signatures were compared with p53-mutation associated genes in breast tumors.
  • RESULTS: Each cell line displayed distinct patterns of p53-dependent gene expression, but cell type specific (basal vs. luminal) commonalities were evident.
  • Further, a common gene expression signature associated with p53 loss across all four cell lines was identified.
  • Moreover, the common cell-line tumor signature excluded genes that were breast cancer subtype-associated, but not downstream of p53.
  • To validate the biological relevance of the common signature, we demonstrated that this gene set predicted relapse-free, disease-specific, and overall survival in independent test data.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Oct 7;23(46):7669-78 [15361840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5824-30 [7954409.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1649-54 [7712469.001]
  • [Cites] Oncogene. 1997 Aug 28;15(9):1079-85 [9285562.001]
  • [Cites] Nature. 1997 Sep 18;389(6648):300-5 [9305847.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Methods Enzymol. 1999;303:179-205 [10349646.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12):1968-73 [10471047.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43 [15701700.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5 [16141321.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):62-9 [16397025.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1011-21 [10572598.001]
  • [Cites] Genes Dev. 2000 Apr 15;14(8):981-93 [10783169.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13009-14 [11069295.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • [Cites] Oncology. 2002;63(1):48-55 [12187071.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):245-51 [12507303.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):292-300 [12619115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Cell. 2003 Aug 8;114(3):323-34 [12914697.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):105-14 [14693816.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4218-26 [15205334.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3667-9 [8339273.001]
  • (PMID = 17150101.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-101227-01; United States / NCI NIH HHS / CA / R25 CA57726; United States / NCI NIH HHS / CA / P50-CA58223-09A1; United States / NCI NIH HHS / CA / R01 CA101227; United States / NIEHS NIH HHS / ES / 5F32ES012374; United States / NCI NIH HHS / CA / P50 CA058223; United States / NIEHS NIH HHS / ES / F32 ES012374; United States / NIEHS NIH HHS / ES / U19 ES011391; United States / NIEHS NIH HHS / ES / U19-ES11391-03; United States / NCI NIH HHS / CA / R25 CA057726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1764759
  •  go-up   go-down


52. Di Gennaro P, Sestini R, Bacci S, Pacini A, Pinzani P, Domenici L, Toscano A, Massi D, Carli P, Genuardi M, Romagnoli P: Tacrolimus causes reduced GLI1 expression and phenotypic changes in the TE 354.T basal cell carcinoma cell line. J Dermatol Sci; 2009 Apr;54(1):52-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tacrolimus causes reduced GLI1 expression and phenotypic changes in the TE 354.T basal cell carcinoma cell line.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Immunosuppressive Agents / pharmacology. Tacrolimus / pharmacology. Transcription Factors / antagonists & inhibitors
  • [MeSH-minor] Blood Coagulation Factors / drug effects. Blood Coagulation Factors / metabolism. Cell Line, Tumor. Gene Expression / drug effects. Humans. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Proto-Oncogene Proteins c-bcl-2 / metabolism. Receptors, Cell Surface / drug effects. Receptors, Cell Surface / metabolism. Receptors, G-Protein-Coupled / drug effects. Receptors, G-Protein-Coupled / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081230.001).
  • [ISSN] 1873-569X
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Blood Coagulation Factors; 0 / GLI1 protein, human; 0 / Immunosuppressive Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RPL29 protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human; 0 / Transcription Factors; 0 / patched receptors; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


53. Ortix C, Lorenzana J, Di Castro C: Coulomb-frustrated phase separation phase diagram in systems with short-range negative compressibility. Phys Rev Lett; 2008 Jun 20;100(24):246402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coulomb-frustrated phase separation phase diagram in systems with short-range negative compressibility.
  • Using numerical techniques and asymptotic expansions we obtain the phase diagram of a paradigmatic model of Coulomb-frustrated phase separation in systems with negative short-range compressibility.
  • The transition from the homogeneous phase to the inhomogeneous phase is generically first order in isotropic three-dimensional systems except for a critical point.
  • Close to the critical point, inhomogeneities are predicted to form a bcc lattice with subsequent transitions to a triangular lattice of rods and a layered structure.
  • Inclusion of a strong anisotropy allows for second- and first-order transition lines joined by a tricritical point.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18643604.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Caussinus E, Hirth F: Asymmetric stem cell division in development and cancer. Prog Mol Subcell Biol; 2007;45:205-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymmetric stem cell division in development and cancer.
  • Asymmetric stem cell division leads to another stem cell via self-renewal, and a second cell type which can be either a differentiating progenitor or a postmitotic cell.
  • The regulation of this balanced process is mainly achieved by polarization of the stem cell along its apical-basal axis and the basal localization and asymmetric segregation of cell fate determinants solely to the differentiating cell.
  • Recent molecular genetic evidence in Drosophila melanogaster suggests that impaired polarity formation in neuroblast stem cells results in symmetric stem cell divisions, whereas defects in progenitor cell differentiation leads to mutant cells that are unable to differentiate but rather continue to proliferate.
  • In both cases, the net result is unrestrained self-renewal of mutant stem cells, eventually leading to hyperproliferation and malignant neoplastic tissue formation.
  • Thus, deregulated stem cells can play a pivotal role in Drosophila tumor formation.
  • In addition, inappropriate activation of pathways promoting the self-renewal of somatic stem cells including defects in asymmetric cell division has been shown to cause neoplastic proliferation and cancer formation.
  • Taken together, these data indicate that evolutionary conserved mechanisms regulate stem and progenitor cell self-renewal and tumor suppression via asymmetric cell division control.
  • [MeSH-major] Cell Division / physiology. Neoplasms / physiopathology. Stem Cells / physiology
  • [MeSH-minor] Animals. Cell Differentiation. Cell Lineage. Cell Polarity. Cell Proliferation. Embryo, Nonmammalian / cytology. Embryo, Nonmammalian / physiology. Humans. Neoplastic Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585502.001).
  • [ISSN] 0079-6484
  • [Journal-full-title] Progress in molecular and subcellular biology
  • [ISO-abbreviation] Prog. Mol. Subcell. Biol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0701498
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


55. Ahn EH, Chang CC, Schroeder JJ: Evaluation of sphinganine and sphingosine as human breast cancer chemotherapeutic and chemopreventive agents. Exp Biol Med (Maywood); 2006 Nov;231(10):1664-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to evaluate the chemotherapeutic and chemopreventive potential of sphingoid bases (sphingosine and sphinganine) using a novel cell culture system of normal human breast epithelial cells (HBEC) developed from breast tissues of healthy women obtained during reduction mammoplasty (Type I HBEC with stem cell characteristics and Type II HBEC with basal epithelial cell phenotypes) and transformed tumorigenic Type I HBEC.
  • Both sphinganine and sphingosine at high concentrations (8-10 lM) arrested the cell cycle at G(2)/M.
  • At concentrations (0.05, 0.1, and 0.5 microM) that are below the growth-inhibitory range, sphingoid bases induced differentiation of Type I HBEC to Type II HBEC, as detected morphologically and via expression of a tumor suppressor protein, maspin, which is a marker of Type II HBEC.
  • [MeSH-major] Apoptosis / drug effects. Cell Cycle / drug effects. Sphingosine / analogs & derivatives. Sphingosine / pharmacology
  • [MeSH-minor] Breast Neoplasms / pathology. Breast Neoplasms / prevention & control. Cell Transformation, Neoplastic. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Female. Humans. Inhibitory Concentration 50. Neoplastic Stem Cells. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060688.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; NGZ37HRE42 / Sphingosine; OWA98U788S / safingol
  •  go-up   go-down


56. Sonneveld E, Jansen HJ, Riteco JA, Brouwer A, van der Burg B: Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol Sci; 2005 Jan;83(1):136-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays.
  • We have established highly sensitive and specific androgen and estrogen reporter cell lines which we have named AR (androgen receptor) and ERalpha (estrogen receptor alpha) CALUX (Chemically Activated LUciferase eXpression), respectively.
  • Both bioassays are member of a panel of CALUX reporter cell lines derived from the human U2-OS osteosarcoma cell line, all using highly selective reporter constructs based with a basal promoter element linked to multimerized response elements, allowing efficient and specific measurement of compounds interfering with androgen, estrogen, progesterone, and glucocorticoid receptors.
  • This cell line was characterized by its stable expression of AR protein, its highly selective response to low levels of different natural and synthetic androgens, and its insignificant response to other nuclear hormone receptor ligands such as estrogens, progestins, and glucocorticoids.
  • The established AR CALUX bioassay proved to excel in terms of easy cell line maintenance, high fold induction range (typical 30 times over solvent control), low minimal detection limit (3.6 pM), and high androgen selectivity.
  • [MeSH-minor] Androgen Receptor Antagonists. Androgens / pharmacology. Cell Line, Tumor. Environmental Pollutants / pharmacology. Estrogens / pharmacology. Genes, Reporter / genetics. Glucocorticoids / pharmacology. Humans. Ligands. Luciferases / genetics. Mammary Tumor Virus, Mouse / genetics. Progestins / pharmacology. Promoter Regions, Genetic / genetics. Receptors, Glucocorticoid / genetics. Receptors, Glucocorticoid / metabolism. Receptors, Progesterone / genetics. Receptors, Progesterone / metabolism. Sensitivity and Specificity. Transfection

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15483189.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Receptor Antagonists; 0 / Androgens; 0 / Environmental Pollutants; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Glucocorticoids; 0 / Ligands; 0 / Progestins; 0 / Receptors, Androgen; 0 / Receptors, Glucocorticoid; 0 / Receptors, Progesterone; 0 / Steroids; EC 1.13.12.- / Luciferases
  •  go-up   go-down


57. Javvadi P, Hertan L, Kosoff R, Datta T, Kolev J, Mick R, Tuttle SW, Koumenis C: Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res; 2010 Mar 1;70(5):1941-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously showed that curcumin radiosensitizes cervical tumor cells without increasing the cytotoxic effects of radiation on normal human fibroblasts.
  • Conversely, overexpressing catalytically active TxnRd1 in HEK293 cells, with low basal levels of TxnRd1, increased their sensitivity to curcumin alone and to the combination of curcumin and ionizing radiation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2000 Feb 15;346 Pt 1:1-8 [10657232.001]
  • [Cites] J Cell Biol. 2008 Apr 21;181(2):189-94 [18411313.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6118-25 [11012663.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2074-83 [11283141.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1025-36 [11704327.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):735-43 [12062620.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6317-27 [12214272.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):536-41 [12243833.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(21):7405-16 [12370288.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6A):3331-5 [12530083.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2425-33 [12894524.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1599-607 [14985701.001]
  • [Cites] Curr Pharm Des. 2004;10(16):1969-77 [15180532.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1611-7 [15090465.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1101-8 [15367704.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6716-24 [15374989.001]
  • [Cites] J Nutr. 2004 Nov;134(11):3213S-3214S [15514312.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1006-11 [8577704.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Aug 5;225(1):268-74 [8769129.001]
  • [Cites] Indian J Exp Biol. 1996 Sep;34(9):845-7 [9014516.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):987-94 [9605422.001]
  • [Cites] J Ethnopharmacol. 1999 Jan;64(1):1-7 [10075116.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25379-85 [10464265.001]
  • [Cites] Anal Biochem. 1965 Apr;11:6-9 [14328648.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54510-7 [15471857.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Feb;132(2):317-21 [15692547.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25284-90 [15879598.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13005-8 [16565519.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):890-8 [16751071.001]
  • [Cites] Semin Cancer Biol. 2006 Dec;16(6):452-65 [17056271.001]
  • [Cites] Biol Pharm Bull. 2007 Jan;30(1):74-8 [17202663.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S115-24 [17259552.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1988-96 [17332326.001]
  • [Cites] J Neurochem. 2007 Jul;102(2):522-38 [17596214.001]
  • [Cites] Acta Pharmacol Sin. 2007 Sep;28(9):1274-304 [17723163.001]
  • [Cites] Biochem Pharmacol. 2008 Feb 15;75(4):787-809 [17900536.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2128-36 [18381954.001]
  • [Cites] Mol Pharmacol. 2008 May;73(5):1491-501 [18252805.001]
  • [Cites] Anal Biochem. 2000 May 15;281(1):77-86 [10847613.001]
  • (PMID = 20160040.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104922-04; United States / NCI NIH HHS / CA / R01 CA104922-04; United States / NCI NIH HHS / CA / R01 CA104922; United States / NCI NIH HHS / CA / R21 CA137398; United States / NCI NIH HHS / CA / CA137398; United States / NCI NIH HHS / CA / CA104922
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 0 / Reactive Oxygen Species; EC 1.8.1.9 / TXNRD1 protein, human; EC 1.8.1.9 / Thioredoxin Reductase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; IT942ZTH98 / Curcumin
  • [Other-IDs] NLM/ NIHMS170969; NLM/ PMC2831122
  •  go-up   go-down


58. Tai KP, Dai XD, Shen YX, Liu BX: Formation and structural anomaly of the metastable phases in an immiscible Ag-Mo system studied by ion beam mixing and molecular dynamics simulation. J Phys Chem B; 2006 Jan 12;110(1):595-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Formation and structural anomaly of the metastable phases in an immiscible Ag-Mo system studied by ion beam mixing and molecular dynamics simulation.
  • For the equilibrium immiscible Ag-Mo system characterized by a large positive heat of formation, the nanosized Ag-Mo multilayered samples are designed and prepared to include sufficient interfacial free energy to elevate their initial energetic states to be higher than that of either the amorphous phase or solid solution and then subject to 200 keV xenon ion irradiation.
  • The results show that a uniform amorphous alloy can be obtained within a composition range, at least, from 25 to 88 atom % of Mo.
  • Interestingly, in the intermediate stage of ion irradiation, a bcc phase, an amorphous phase, and an order (bcc)-disorder coexisting state appear simultaneously in the Ag12Mo88 multilayered sample and extend over the entire bright field image with unanimously homogeneous composition.
  • In thermodynamic modeling, a Gibbs free energy diagram of the Ag-Mo system is constructed, based on Miedema's model, and suggests that within a narrow composition regime of 85-90 atom % of Mo, the energy difference between the bcc and the amorphous phases is extremely small, which is probably the very reason for the order-disorder coexisting state to appear.
  • In atomistic modeling, an ab initio derived Ag-Mo potential is applied to perform molecular dynamics simulations.
  • The simulations not only determine an intrinsic glass-forming ability/range (GFA/GFR) of the Ag-Mo system to be from 10 to 88 atom % of Mo but also reveal the possibility of the formation/appearance of a crystalline and amorphous mixture in a narrow composition regime of 88-92 atom % of Mo.
  • Apparently, the theoretical results are in excellent agreement and/or compatible with the experimental observations in ion beam mixing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471572.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Ribeiro BM, Crema E, Rodrigues V Jr: Analysis of the cellular immune response in patients with the digestive and indeterminate forms of Chagas' disease. Hum Immunol; 2008 Aug;69(8):484-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the cellular immune response in patients with the digestive and indeterminate forms of Chagas' disease.
  • The commitment of the digestive organs observed in patients during the chronic phase of Chagas' disease is mainly attributed to neuronal damage induced by immune and inflammatory processes elicited by the presence of Trypanosoma cruzi.
  • Here we compare the cellular immune response in patients with the digestive and indeterminate forms of Chagas' disease on the basis of lymphocyte proliferation and cytokine production after antigen or mitogen stimulation.
  • No significant differences between patients groups were observed on proliferative response or on tumor necrosis factor (TNF)-alpha and interleukin (IL)-10 levels, although IL-10 achieves higher levels than TNF-alpha after T. cruzi antigen stimulation.
  • Interferon (IFN)-gamma basal production was significantly higher in the digestive form and IL-4 was significantly higher in patients with megaesophagus when compared with patients with megacolon.
  • These results indicated that patients with the digestive form of Chagas' disease do not suffer immune suppression and that the cytokine balance favors a strong inflammatory reaction in patients with the digestive form, which may contribute to lesions of the mioenteric nervous system.
  • [MeSH-major] Chagas Disease / immunology. Cytokines / biosynthesis. Lymphocyte Activation. Trypanosoma cruzi / immunology
  • [MeSH-minor] Animals. Cell Proliferation. Humans. Immunity, Cellular. Interferon-gamma / biosynthesis. Interferon-gamma / immunology. Interleukin-10 / biosynthesis. Interleukin-10 / immunology. Interleukin-4 / biosynthesis. Interleukin-4 / immunology. Leukocytes, Mononuclear / immunology. Tumor Necrosis Factor-alpha / biosynthesis. Tumor Necrosis Factor-alpha / immunology

  • Genetic Alliance. consumer health - Chagas Disease.
  • MedlinePlus Health Information. consumer health - Chagas Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18582517.001).
  • [ISSN] 0198-8859
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


60. Scortegagna M, Martin RJ, Kladney RD, Neumann RG, Arbeit JM: Hypoxia-inducible factor-1alpha suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. Cancer Res; 2009 Mar 15;69(6):2638-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, in selected contexts, HIF-1 is a tumor suppressor coordinating hypoxic cell cycle suppression and apoptosis.
  • Prior studies focused on HIF-1 function in established malignancy; however, little is known about its role during the entire process of carcinogenesis from neoplasia induction to malignancy.
  • Transgenic papillomas appeared earlier and were more numerous (6 +/- 3 transgenic versus 2 +/- 1.5 nontransgenic papillomas per mouse), yet they were more differentiated, their proliferation was lower, and their malignant conversion was profoundly inhibited (7% in transgenic versus 40% in nontransgenic mice).
  • Transgenic basal keratinocytes up-regulated the HIF-1 target N-myc downstream regulated gene-1, a known tumor suppressor gene in human malignancy, and its expression was maintained in transgenic papillomas and cancer.
  • Thus, HIF-1 can function as a tumor suppressor through transactivation of genes that are themselves targets for negative selection in human cancers.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 1;60(3):749-55 [10676663.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):157-69 [17060462.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1196-206 [11158306.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6669-73 [11559532.001]
  • [Cites] Genes Dev. 2001 Oct 1;15(19):2520-32 [11581158.001]
  • [Cites] Mol Carcinog. 2001 Oct;32(2):100-9 [11746822.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2493-7 [11980639.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):630-9 [12101110.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):359-69 [12482987.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1731-6 [12702552.001]
  • [Cites] Mol Cell Biochem. 2003 Aug;250(1-2):91-105 [12962147.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] J Pathol. 2004 Mar;202(3):321-9 [14991897.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5675-81 [15184886.001]
  • [Cites] BMC Genet. 2004 Sep 2;5:27 [15341671.001]
  • [Cites] Bull Cancer. 1978;65(3):271-9 [102384.001]
  • [Cites] Carcinogenesis. 1988 Oct;9(10):1801-10 [3168159.001]
  • [Cites] Carcinogenesis. 1990 Nov;11(11):2071-3 [2225343.001]
  • [Cites] Carcinogenesis. 1993 Mar;14(3):335-40 [8453708.001]
  • [Cites] Carcinogenesis. 1993 Nov;14(11):2353-8 [8242866.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):88-91 [8538748.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):335-47 [17418410.001]
  • [Cites] Cell. 2007 Apr 6;129(1):111-22 [17418790.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] PLoS One. 2007;2(9):e844 [17786215.001]
  • [Cites] Oncogene. 2007 Oct 18;26(48):6885-95 [17525749.001]
  • [Cites] J Nutr Biochem. 2008 Jan;19(1):1-7 [17588734.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):51-6 [18046334.001]
  • [Cites] Exp Dermatol. 2008 Apr;17(4):335-42 [18279341.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3343-54 [18199827.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Mol Nutr Food Res. 2008 Nov;52(11):1289-99 [18435490.001]
  • [Cites] Cancer Surv. 1996;26:7-34 [8783566.001]
  • [Cites] J Cell Biochem. 1997 Feb;64(2):217-24 [9027582.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3150-3 [9679983.001]
  • [Cites] Oncogene. 1998 Jul 23;17(3):303-11 [9690512.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4439-44 [9766676.001]
  • [Cites] Carcinogenesis. 1998 Dec;19(12):2107-13 [9886564.001]
  • [Cites] Cell Cycle. 2004 Jul;3(7):853-4 [15190211.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48930-40 [15377670.001]
  • [Cites] Mol Cell. 2005 Mar 18;17(6):793-803 [15780936.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2583-90 [15814637.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3171-8 [15833847.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):393-400 [16010420.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2725-31 [16510593.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2433-40 [16380993.001]
  • [Cites] Nature. 2006 Apr 27;440(7088):1222-6 [16642001.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5007-9 [16951213.001]
  • [Cites] Curr Opin Cell Biol. 2006 Dec;18(6):598-608 [17046224.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1541-5 [10749120.001]
  • (PMID = 19276359.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090722-06; United States / NCI NIH HHS / CA / R01 CA090722; United States / NCI NIH HHS / CA / R01 CA090722-06; United States / NCI NIH HHS / CA / R01 CA90722
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Cell Cycle Proteins; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / Selenbp1 protein, mouse; 0 / Selenium-Binding Proteins; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS135119; NLM/ PMC2756430
  •  go-up   go-down


61. Imai K, Togami H, Okamoto T: Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem; 2010 May 28;285(22):16538-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed that G9a significantly inhibited basal, as well as, the induced HIV-1 gene expression by tumor necrosis factor-alpha or Tat.
  • [MeSH-minor] Antigens, Viral / chemistry. Cell Line. Chromatin Immunoprecipitation. HIV Long Terminal Repeat. HeLa Cells. Humans. Protein Structure, Tertiary. RNA Interference. T-Lymphocytes / virology. Virus Replication

  • Genetic Alliance. consumer health - HIV.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2007 Jan 24;26(2):424-35 [17245432.001]
  • [Cites] EMBO J. 2007 Jan 24;26(2):412-23 [17245431.001]
  • [Cites] Cell. 2007 Feb 23;128(4):707-19 [17320508.001]
  • [Cites] Nature. 2007 May 24;447(7143):407-12 [17522673.001]
  • [Cites] Mol Cell. 2007 Aug 17;27(4):596-608 [17707231.001]
  • [Cites] EMBO J. 2007 Dec 12;26(24):4985-95 [18007589.001]
  • [Cites] EMBO Rep. 2008 Mar;9(3):267-72 [18239689.001]
  • [Cites] Retrovirology. 2006;3:7 [16412247.001]
  • [Cites] EMBO J. 2008 Oct 22;27(20):2691-701 [18818693.001]
  • [Cites] Nat Struct Mol Biol. 2008 Nov;15(11):1176-83 [18953337.001]
  • [Cites] J Biol Chem. 2008 Nov 21;283(47):32198-208 [18809684.001]
  • [Cites] AIDS Res Hum Retroviruses. 2009 Feb;25(2):207-12 [19239360.001]
  • [Cites] J Immunol. 2009 Mar 15;182(6):3688-95 [19265147.001]
  • [Cites] J Biol Chem. 2009 Mar 13;284(11):6782-9 [19136668.001]
  • [Cites] PLoS Pathog. 2009 Jun;5(6):e1000495 [19557157.001]
  • [Cites] PLoS Pathog. 2009 Aug;5(8):e1000554 [19696893.001]
  • [Cites] Retrovirology. 2009;6:111 [19961595.001]
  • [Cites] FEBS J. 2009 Dec;276(23):7124-33 [20064163.001]
  • [Cites] EMBO J. 2009 Aug 5;28(15):2231-43 [19478796.001]
  • [Cites] Mol Cell. 2007 Feb 9;25(3):473-81 [17289593.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] J Virol. 2000 Aug;74(15):6790-9 [10888618.001]
  • [Cites] Nature. 2000 Aug 10;406(6796):593-9 [10949293.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25309-17 [11316813.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Cell. 2002 Feb 22;108(4):475-87 [11909519.001]
  • [Cites] Genes Dev. 2002 Apr 15;16(8):919-32 [11959841.001]
  • [Cites] Science. 2002 May 10;296(5570):1132-6 [12004135.001]
  • [Cites] Genes Dev. 2002 Jul 15;16(14):1779-91 [12130538.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):735-8 [12700765.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):14996-5000 [12586828.001]
  • [Cites] J Cell Sci. 2003 Jun 1;116(Pt 11):2117-24 [12730288.001]
  • [Cites] EMBO J. 2003 Dec 15;22(24):6550-61 [14657027.001]
  • [Cites] Mol Cell. 2003 Dec;12(6):1591-8 [14690610.001]
  • [Cites] Mol Cell. 2004 Jun 18;14(6):727-38 [15200951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11257-62 [15269344.001]
  • [Cites] J Biol Chem. 1982 Feb 25;257(4):2041-8 [6173384.001]
  • [Cites] J Immunol. 1988 Feb 15;140(4):1117-22 [2449497.001]
  • [Cites] J Immunol. 1989 Jan 15;142(2):431-8 [2463307.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(7):2365-8 [2784570.001]
  • [Cites] J Virol. 1991 Sep;65(9):4645-53 [1678437.001]
  • [Cites] J Virol. 1991 Dec;65(12):6790-9 [1942252.001]
  • [Cites] EMBO J. 1993 Aug;12(8):3249-59 [8344262.001]
  • [Cites] EMBO J. 1996 Mar 1;15(5):1112-20 [8605881.001]
  • [Cites] Nature. 1997 Sep 18;389(6648):251-60 [9305837.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3327-40 [9407026.001]
  • [Cites] Cell. 1998 Jun 26;93(7):1231-40 [9657155.001]
  • [Cites] Endocr Rev. 2005 Apr;26(2):147-70 [15479858.001]
  • [Cites] Genes Dev. 2005 Apr 1;19(7):815-26 [15774718.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26701-13 [15929986.001]
  • [Cites] Lancet. 2005 Aug 13-19;366(9485):549-55 [16099290.001]
  • [Cites] EMBO J. 2006 Jan 11;25(1):139-49 [16319923.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Feb;50(2):547-55 [16436709.001]
  • [Cites] Nat Cell Biol. 2006 Feb;8(2):188-94 [16415856.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):37-50 [16485345.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12495-505 [16540471.001]
  • [Cites] FEBS J. 2006 Jul;273(14):3121-35 [16857008.001]
  • [Cites] Retrovirology. 2006;3:69 [17034647.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3089-103 [17085482.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):77-90 [16799634.001]
  • [CommentIn] Epigenomics. 2010 Aug;2(4):506-7 [22232790.001]
  • (PMID = 20335163.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Azepines; 0 / BIX 01294; 0 / Histocompatibility Antigens; 0 / Histones; 0 / Quinazolines; EC 2.1.1.43 / EHMT2 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Other-IDs] NLM/ PMC2878073
  •  go-up   go-down


62. Bunyapaiboonsri T, Yoiprommarat S, Khonsanit A, Komwijit S: Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080. J Nat Prod; 2008 May;71(5):891-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080.
  • New phenolic mono- and digalactopyranosides (1 and 2), their aglycone KS-501a (3), and a new phenolic 4-O-methylglucopyranoside (4) were isolated from the filamentous fungus Acremonium sp. BCC 14080.
  • Structures of these compounds were elucidated by extensive MS and NMR spectroscopic analyses.
  • Compound 1 displayed anti-HSV-1 activity with an IC(50) value of 7.2 microM.
  • Compound 3 exhibited activity against Plasmodium falciparum K1 with an IC(50) value of 9.9 microM.
  • [MeSH-major] Acremonium / chemistry. Antiviral Agents / isolation & purification. Antiviral Agents / pharmacology. Glycosides / isolation & purification. Glycosides / pharmacology. Herpesvirus 1, Human / drug effects. Phenols / isolation & purification. Phenols / pharmacology. Plasmodium falciparum / drug effects
  • [MeSH-minor] Animals. Cercopithecus aethiops. Drug Screening Assays, Antitumor. Humans. Hydroxybenzoates / chemistry. Hydroxybenzoates / isolation & purification. Hydroxybenzoates / pharmacology. Inhibitory Concentration 50. Molecular Structure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363379.001).
  • [ISSN] 0163-3864
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Glycosides; 0 / Hydroxybenzoates; 0 / Phenols; 120634-86-8 / KS 501
  •  go-up   go-down


63. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE, Sandlund JT, Rivera GK, Evans WE, Relling MV, Pui CH: Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA; 2007 Mar 21;297(11):1207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia.
  • CONTEXT: Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia.
  • OBJECTIVES: To investigate the cumulative incidence of secondary neoplasms in pediatric patients treated for acute lymphoblastic leukemia over 30 years and to characterize late-occurring tumors.
  • MAIN OUTCOME MEASURES: Cumulative incidences of secondary neoplasms in first remission and standard incidence ratios of observed rates compared with rates of cancer development in the general US population.
  • RESULTS: Secondary neoplasms developed as the first event in 123 patients and comprised 46 myeloid malignancies, 3 lymphomas, 14 basal cell carcinomas, 16 other carcinomas, 6 sarcomas, 16 meningiomas, and 22 other brain tumors.
  • The cumulative incidence of secondary neoplasm was 4.17% (SE, 0.46%) at 15 years and increased substantially after 20 years, reaching 10.85% (SE, 1.27%) at 30 years.
  • When meningiomas and basal cell carcinomas were excluded, the overall cumulative incidence was 3.99% (SE, 0.44%) at 15 years and 6.27% (SE, 0.83%) at 30 years, representing a 13.5-fold increase in overall risk compared with the general population.
  • The cumulative incidence of each tumor type at 30 years was 2.19% (SE, 0.32%) for myeloid malignancy, 0.17% (SE, 0.10%) for lymphoma, 3.00% (SE, 0.59%) for brain tumor, 4.91% (SE, 1.04%) for carcinoma, and 0.57% (SE, 0.37%) for sarcoma.
  • CONCLUSIONS: The cumulative incidence of secondary neoplasms increases steadily over 30 years after treatment of acute lymphoblastic leukemia.
  • Although the majority of the late-occurring secondary neoplasms are low-grade tumors, the increase in incidence of more aggressive malignant neoplasms is significantly higher than expected in the general population.
  • These results suggest that lifelong follow-up of acute lymphoblastic leukemia survivors is needed to ascertain the full impact of treatment and other leukemia-related factors on secondary neoplasm development.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374815.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-60419; United States / NCI NIH HHS / CA / CA-71907; United States / NCI NIH HHS / CA / CA-78224; United States / NIGMS NIH HHS / GM / GM-61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Iijima M, Brantley WA, Baba N, Alapati SB, Yuasa T, Ohno H, Mizoguchi I: Micro-XRD study of beta-titanium wires and infrared soldered joints. Dent Mater; 2007 Sep;23(9):1051-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micro-XRD study of beta-titanium wires and infrared soldered joints.
  • OBJECTIVE: The purpose of this study was to investigate the metallurgical phases in beta-titanium soldered joints prepared by infrared soldering, using the Micro X-ray diffraction technique (Micro-XRD), and to characterize the Vickers hardness in the soldered beta-titanium wires.
  • METHODS: Beta-titanium wires with cross-section dimensions of 0.032in.x0.032in. (TMA, Ormco), and both titanium-based solder (Ti-30Ni-20Cu, Selec) and silver-based solder (Ag-22Cu-17Zn-5Sn, Tomy) were selected.
  • Soldering was performed using infrared radiation (RS-1, Morita) under argon atmosphere.
  • Micro-XRD analyses were performed at room temperature.
  • Micro-XRD spectra were obtained for the boundary region of the soldered beta-titanium wires using 50microm and 10microm diameter analysis regions.
  • Hardness was measured at 30microm intervals from boundary of the diffusion layer and beta-titanium wire.
  • The Kruskal-Wallis test with the Bonferroni and Wilcoxson Mann-Whitney tests for nonparametric means were employed as statistical methods (P<0.05).
  • RESULTS: For both types of soldered beta-titanium samples, the Micro-XRD spectra contained four major peaks for body-centered cubic (bcc) beta-titanium.
  • Additional peaks at about 41 and 45 degrees are attributed to Cu-Ti intermetallic phase(s), which may be metastable under soldering conditions.
  • The diffusion layer had greater hardness than bulk beta-titanium for both types of soldered specimens (P<0.05).
  • SIGNIFICANCE: Soldering of beta-titanium orthodontic wire by infrared radiation may be acceptable for clinical use, since Micro-XRD spectra revealed that both types of soldered specimens largely retained the bcc beta-titanium structure.
  • Further research is needed to investigate the mechanical properties and corrosion behavior of infrared-soldered beta-titanium wire.
  • [MeSH-major] Dental Soldering. Orthodontic Wires. Titanium / chemistry
  • [MeSH-minor] Alloys / chemistry. Copper / chemistry. Diffusion. Electron Probe Microanalysis. Hardness. Humans. Infrared Rays. Materials Testing. Mechanics. Metallurgy. Microspectrophotometry. Nickel / chemistry. Silver / chemistry. Surface Properties. Tin / chemistry. X-Ray Diffraction. Zinc / chemistry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • Hazardous Substances Data Bank. TIN .
  • Hazardous Substances Data Bank. TITANIUM .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178150.001).
  • [ISSN] 0109-5641
  • [Journal-full-title] Dental materials : official publication of the Academy of Dental Materials
  • [ISO-abbreviation] Dent Mater
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alloys; 3M4G523W1G / Silver; 7440-31-5 / Tin; 789U1901C5 / Copper; 7OV03QG267 / Nickel; D1JT611TNE / Titanium; J41CSQ7QDS / Zinc
  •  go-up   go-down


65. Berry NB, Fan M, Nephew KP: Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol Endocrinol; 2008 Jul;22(7):1535-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two receptor lysines, K302 and K303, located in the hinge-region of ERalpha, serve multiple regulatory functions, and we examined whether these might also regulate receptor polyubiquitination, turnover, and receptor-protein interactions.
  • In the unliganded state, ERalpha-AA displayed rapid polyubiquitination and enhanced basal turnover, as compared with wtERalpha, due to its elevated association with the ubiquitin ligase carboxy terminus of Hsc70-interacting protein (CHIP) and the proteasome-associated cochaperone Bag1.
  • The reduced stability of ERalpha-AA in the unliganded state and the increased stability of ERalpha-AA in the liganded state were concordant with reporter gene assays demonstrating that ERalpha-AA has lower basal activity but higher E2 inducibility than wtERalpha.
  • These data provide the first evidence that K302/303 protect ERalpha from basal degradation and are necessary for efficient E2- and ICI-induced turnover in breast cancer cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. L-Lysine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2004 Nov 30;227(1-2):53-65 [15501584.001]
  • [Cites] Endocrinology. 1984 Feb;114(2):629-37 [6690295.001]
  • [Cites] Endocrinology. 1999 Dec;140(12):5828-40 [10579349.001]
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):4613-7 [10671488.001]
  • [Cites] Genes Dev. 2000 Feb 15;14(4):422-34 [10691735.001]
  • [Cites] Mol Cell. 2000 Jun;5(6):939-48 [10911988.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4026-9 [10945602.001]
  • [Cites] Cell. 2000 Dec 8;103(6):843-52 [11136970.001]
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):93-6 [11146632.001]
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):15-23 [11146621.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18375-83 [11279135.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2076-84 [11448926.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5771-7 [11479214.001]
  • [Cites] Front Biosci. 2001 Aug 1;6:D954-9 [11487464.001]
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35684-92 [11473106.001]
  • [Cites] Endocrinology. 1984 Jul;115(1):143-53 [6734512.001]
  • [Cites] Endocrinology. 1986 Nov;119(5):2038-46 [3533520.001]
  • [Cites] Mol Endocrinol. 1992 Jan;6(1):132-40 [1738366.001]
  • [Cites] Mol Endocrinol. 1992 Feb;6(2):157-67 [1569962.001]
  • [Cites] EMBO J. 1992 Oct;11(10):3681-94 [1327748.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Dec;46(6):663-72 [8274400.001]
  • [Cites] J Biol Chem. 1994 Nov 11;269(45):27894-9 [7961721.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Aug 4;213(1):24-31 [7639742.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Mol Endocrinol. 1996 Jun;10(6):705-12 [8776730.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1997;37:297-326 [9131255.001]
  • [Cites] Endocr Rev. 1997 Jun;18(3):306-60 [9183567.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3330-9 [9584173.001]
  • [Cites] Mol Endocrinol. 1998 Jun;12(6):842-54 [9626660.001]
  • [Cites] Biochem Pharmacol. 1998 Sep 15;56(6):675-82 [9751071.001]
  • [Cites] Cell. 1998 Dec 23;95(7):927-37 [9875847.001]
  • [Cites] Mol Endocrinol. 2004 Nov;18(11):2603-15 [15284335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1858-62 [10051559.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3748-59 [10207098.001]
  • [Cites] FEBS Lett. 1999 Apr 1;448(1):160-6 [10217432.001]
  • [Cites] Mol Endocrinol. 1999 Sep;13(9):1435-48 [10478836.001]
  • [Cites] Mol Endocrinol. 1999 Sep;13(9):1522-34 [10478843.001]
  • [Cites] Endocr Rev. 2004 Dec;25(6):869-98 [15583021.001]
  • [Cites] EMBO J. 2004 Dec 8;23(24):4813-23 [15538384.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9199-208 [15604293.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):13097-104 [15657064.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Mar;94(4):347-59 [15857754.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):761-72 [16175177.001]
  • [Cites] Mol Endocrinol. 2005 Nov;19(11):2671-84 [15961505.001]
  • [Cites] Mol Endocrinol. 2005 Dec;19(12):2901-14 [16037132.001]
  • [Cites] Mol Endocrinol. 2006 Jul;20(7):1479-93 [16497729.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):79-86 [16713253.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18487-92 [17130446.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5794-9 [17392432.001]
  • [Cites] J Mol Biol. 2007 May 4;368(3):729-41 [17367809.001]
  • [Cites] Breast Cancer Res Treat. 2007 May;103(1):37-44 [17033922.001]
  • [Cites] Semin Cancer Biol. 2001 Oct;11(5):339-52 [11562176.001]
  • [Cites] Curr Biol. 2001 Oct 16;11(20):1569-77 [11676916.001]
  • [Cites] Curr Opin Investig Drugs. 2001 Nov;2(11):1606-10 [11763165.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Dec 21;289(5):1099-105 [11741305.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):133-40 [11902563.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S55-61 [11927289.001]
  • [Cites] Mol Endocrinol. 2002 May;16(5):947-60 [11981030.001]
  • [Cites] Cell Mol Life Sci. 2002 May;59(5):821-31 [12088282.001]
  • [Cites] Mol Endocrinol. 2003 Mar;17(3):356-65 [12554766.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):695-707 [12667452.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36547-55 [12835317.001]
  • [Cites] Mol Endocrinol. 2003 Oct;17(10):2013-27 [12855746.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):207-21 [14672741.001]
  • [Cites] Cell Stress Chaperones. 2003 Fall;8(3):225-31 [14984055.001]
  • (PMID = 18388150.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085289; United States / NCI NIH HHS / CA / U54 CA113001; United States / NCI NIH HHS / CA / CA 085289; United States / NCI NIH HHS / CA / CA 113001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Estrogen Receptor alpha; 0 / Ubiquitin; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol; EC 3.4.25.1 / Proteasome Endopeptidase Complex; K3Z4F929H6 / Lysine; OF5P57N2ZX / Alanine
  • [Other-IDs] NLM/ PMC2453605
  •  go-up   go-down


66. Liboutet M, Portela M, Delestaing G, Vilmer C, Dupin N, Gorin I, Saiag P, Lebbé C, Kerob D, Dubertret L, Grandchamp B, Basset-Seguin N, Soufir N: MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas. J Invest Dermatol; 2006 Jul;126(7):1510-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas.
  • In this study, we assessed the role of melanocortin 1 receptor (MC1R) variants and of two patched (PTCH) polymorphisms (c.3944C>T (P1315L), insertion 18 bp IVS1-83) as risk factors for basal cell carcinoma (BCC) in the French population.
  • The population investigated comprised 126 BCC patients who were enrolled on the basis of specific criteria (multiple and/or familial BCC and/or onset before the age of 40 years and/or association with another tumor)--and 151 controls matched for ethnicity, age, and sex.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Polymorphism, Genetic. Receptor, Melanocortin, Type 1 / genetics. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. European Continental Ancestry Group / genetics. Female. France / ethnology. Gene Frequency. Genetic Predisposition to Disease. Hair Color. Humans. Male. Middle Aged. Odds Ratio. Prospective Studies. Regression Analysis. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645598.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Melanocortin, Type 1; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


67. Han P, Dou F, Li F, Zhang X, Zhang YW, Zheng H, Lipton SA, Xu H, Liao FF: Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation. J Neurosci; 2005 Dec 14;25(50):11542-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alzheimer's disease is cytopathologically characterized by loss of synapses and neurons, neuritic amyloid plaques consisting of beta-amyloid (Abeta) peptides, and neurofibrillary tangles consisting of hyperphosphorylated tau protein in susceptible brain regions.
  • In addition, we show that overexpression of APP or its non-amyloidogenic homolog amyloid precursor-like protein 1 suppresses both basal and stress-induced CDK5 activation.
  • [MeSH-minor] Animals. Cell Line, Tumor. Enzyme Activation / genetics. Humans. Mice. Mice, Knockout. Phosphorylation. Protein Structure, Tertiary / genetics. Rats. Rats, Sprague-Dawley

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354912.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD29587; United States / NIA NIH HHS / AG / R01 AG024895; United States / NINDS NIH HHS / NS / R01 NS046673
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Enzyme Inhibitors; 0 / Neuroprotective Agents; 0 / tau Proteins; EC 2.7.11.22 / Cyclin-Dependent Kinase 5
  •  go-up   go-down


68. Kaeb S, Landthaler M, Hohenleutner U: Confocal laser scanning microscopy--evaluation of native tissue sections in micrographic surgery. Lasers Med Sci; 2009 Sep;24(5):819-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Micrographic surgery is mainly used for excising basal cell carcinomas in high-risk body sites.
  • We examined the margins of 52 excised basal cell carcinomas by means of CM, and compared the results to conventional histological findings.
  • The morphologic features of tumors seen in CM corresponded well to conventional light microscopy.
  • If a tumor is clearly detectable by means of CM, the procedure of micrographic surgery can be accelerated.
  • Applicability of CM is limited because of an inconsistent image quality that does not allow a reliable detection of small tumor nests.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Microscopy, Confocal / methods. Mohs Surgery / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2003 Aug;29(8):839-46 [12859385.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Cutan Med Surg. 2007 Jan-Feb;11(1):19-30 [17274935.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] Lasers Surg Med. 2007 Oct;39(9):696-705 [17960751.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1470-8 [15606734.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • (PMID = 19277819.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G: Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas; 2008 Mar;36(2):178-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the expression of thioredoxin-interacting protein (TXNIP) during hypoxia and its dependency on hypoxia-inducible factor 1alpha (HIF-1alpha) in pancreatic cancer cell lines.
  • Panc-1 pancreatic cancer cells with low endogenous TXNIP expression were stably transfected with TXNIP, and cell survival and response to platinum cancer agents were tested.
  • Overexpression of TXNIP in the Panc-1 cells resulted in a higher basal apoptosis and increased sensitivity to cisplatin and oxaliplatin.
  • CONCLUSIONS: Thioredoxin-interacting protein, a putative tumor suppressor gene, is induced in response to hypoxia in a HIF-1alpha-dependent manner in pancreatic cancer cells, resulting in increased apoptosis and increased sensitivity to platinum anticancer therapy.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Carrier Proteins / metabolism. Gene Expression Regulation, Neoplastic. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Apoptosis. Cell Hypoxia. Cell Line, Tumor. Cell Survival / drug effects. Cisplatin / pharmacology. Cisplatin / therapeutic use. Humans. Immunohistochemistry. Mutation. Organoplatinum Compounds / pharmacology. Organoplatinum Compounds / therapeutic use. RNA Interference. RNA, Small Interfering / metabolism. Thioredoxins / metabolism. Tissue Array Analysis. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376310.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA077204; United States / NCI NIH HHS / CA / CA109552; United States / NCI NIH HHS / CA / CA90821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Organoplatinum Compounds; 0 / RNA, Small Interfering; 0 / TXN protein, human; 0 / TXNIP protein, human; 04ZR38536J / oxaliplatin; 52500-60-4 / Thioredoxins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


70. Wang Z, Lee HJ, Chai Y, Hu H, Wang L, Zhang Y, Jiang C, Lü J: Persistent p21Cip1 induction mediates G(1) cell cycle arrest by methylseleninic acid in DU145 prostate cancer cells. Curr Cancer Drug Targets; 2010 May;10(3):307-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent p21Cip1 induction mediates G(1) cell cycle arrest by methylseleninic acid in DU145 prostate cancer cells.
  • The induction of G(1) cell cycle arrest and apoptosis by second-generation selenium compounds (e.g., methylselenol precursors such as methylseleninic acid, MSeA) may contribute to their anti-cancer activities.
  • However, whether these CDKIs play a critical mediator role in G(1) arrest and apoptosis by MSeA has not been addressed.
  • In p53-wild type LNCaP PCa cells and p53-null PC-3 PCa cells, MSeA modestly and transiently upregulated p21Cip1 protein level, subsiding to basal level by 24 h, without affecting P27Kip1 abundance in the same duration.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. G1 Phase / drug effects. Organoselenium Compounds / pharmacology. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Caspases / metabolism. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p27. Cyclin-Dependent Kinases / metabolism. Dose-Response Relationship, Drug. Humans. Intracellular Signaling Peptides and Proteins / metabolism. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Mutation. RNA Interference. RNA, Messenger / metabolism. Time Factors. Transfection. Tumor Suppressor Protein p53 / genetics. Up-Regulation. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20370687.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA126880; United States / NCI NIH HHS / CA / CA95642
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 0 / Organoselenium Compounds; 0 / RNA, Messenger; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 28274-57-9 / methylselenic acid; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.4.22.- / Caspases
  •  go-up   go-down


71. Dugina VB, Ermilova VD, Chemeris GIu, Chipysheva TA: [Actins and keratins in the diagnosis of human basal-like breast cancer]. Arkh Patol; 2010 Mar-Apr;72(2):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Actins and keratins in the diagnosis of human basal-like breast cancer].
  • The most common forms of luminal breast cancer (BC) were compared with basal-like and Her2/neu3+ BC.
  • Basal-like BC cells (ER/PR/Her2/ neu-) were regularly stained with antibodies to basal keratins 5/6 and 17, smooth muscle alpha-actin, and p63.
  • The solid regions had beta-actin staining with disappearance in the scirrhous component. beta-actin and basal keratins were also observed in metaplastic BC with ER/PR/Her2/neu3+.
  • Immunomorphology using cytoskeletal markers along with the expression of steroid hormone and Her2/neu receptors may be used in the diagnosis of basal-like forms of BC.
  • [MeSH-major] Actins / biosynthesis. Biomarkers, Tumor / biosynthesis. Breast Neoplasms. Gene Expression Regulation, Neoplastic. Keratins / biosynthesis. Neoplasm Proteins / biosynthesis. Neoplasms, Basal Cell

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698309.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


72. Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H, Kronqvist P, Jaakkola PM: Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res; 2006 Feb 15;12(4):1080-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.
  • EXPERIMENTAL DESIGN: The expression of PHD2 was studied from paraffin-embedded normal tissue (n = 21) and head and neck squamous cell carcinoma (HNSCC; n = 44) by immunohistochemistry.
  • Further studies included PHD2 mRNA detection and HIF-1alpha immunohistochemistry from HNSCC specimens as well as PHD2 immunocytochemistry from HNSCC-derived cell lines.
  • In epithelium, the basal proliferating layer also shows strong expression, whereas the more differentiated epithelium shows little or no PHD2 expression.
  • Endogenously high nuclear PHD2 is seen in a subset of HNSCC-derived cell lines.
  • Finally, although most of the tumor regions with high PHD2 expression show down-regulated HIF-1alpha, regions with simultaneous HIF-1alpha and PHD2 expression could be detected.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Nucleus / metabolism. Head and Neck Neoplasms / pathology. Immediate-Early Proteins / genetics. Procollagen-Proline Dioxygenase / genetics
  • [MeSH-minor] Active Transport, Cell Nucleus. Blotting, Western. Cell Hypoxia. Cell Line. Dioxygenases. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. HeLa Cells. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Hypoxia-Inducible Factor-Proline Dioxygenases. Immunohistochemistry. Isoenzymes / genetics. Isoenzymes / metabolism. Microscopy, Confocal. Neoplasm Invasiveness. RNA, Messenger / genetics. RNA, Messenger / metabolism. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16489060.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Immediate-Early Proteins; 0 / Isoenzymes; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 1.13.11.- / Dioxygenases; EC 1.14.11.2 / EGLN1 protein, human; EC 1.14.11.2 / Procollagen-Proline Dioxygenase; EC 1.14.11.29 / EGLN3 protein, human; EC 1.14.11.29 / Hypoxia-Inducible Factor-Proline Dioxygenases
  •  go-up   go-down


73. Inoue S, Inoue M, Takahashi H, Inoue A, Kunitomo K, Fujii H: [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy]. Gan To Kagaku Ryoho; 2008 Feb;35(2):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Capecitabine. Female. Humans. Immunotherapy. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Middle Aged. Neoplasm Staging. Recurrence. Tomography, X-Ray Computed. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281774.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Antoniades D, Epivatianos A, Markopoulos A, Kolokotronis A, Zaraboukas T: Coexistence of mucous retention cyst and basal cell adenoma arising from the lining epithelium of the cyst. Report of two cases. Med Princ Pract; 2009;18(3):248-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of mucous retention cyst and basal cell adenoma arising from the lining epithelium of the cyst. Report of two cases.
  • OBJECTIVE: To report 2 cases of coexisting mucous retention cyst and basal cell adenoma arising from the lining epithelium of the cyst.
  • CLINICAL PRESENTATION AND INTERVENTION: Two cases of painless swellings, well-demarcated, soft to palpation, and located in the submucosa of the upper lip were clinically examined with the provisional diagnosis of mucocele or salivary gland tumor.
  • The trabeculae were composed of basal and low columnar cells that sometimes formed small duct-like structures.
  • Based on the results, a diagnosis of coexisting mucous retention cysts and basal cell adenomas arising from the lining epithelium of cysts was made.
  • CONCLUSION: The coexistence of mucous retention cysts and basal cell adenomas arising from the lining epithelium of the cyst is reported.

  • MedlinePlus Health Information. consumer health - Salivary Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19349732.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


75. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, van der Pluijm G: Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res; 2007 Sep 15;67(18):8742-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because EMT is involved in cancer, we investigated whether BMP7 plays a role in breast cancer growth and metastasis.
  • In line with these clinical observations, BMP7 expression is inversely related to tumorigenicity and invasive behavior of human breast cancer cell lines.
  • Moreover, BMP7 decreased the expression of vimentin, a mesenchymal marker associated with invasiveness and poor prognosis, in human MDA-MB-231 (MDA-231)-B/Luc(+) breast cancer cells under basal and transforming growth factor-beta (TGF-beta)-stimulated conditions.
  • Furthermore, in a well-established bone metastasis model using whole-body bioluminescent reporter imaging, stable overexpression of BMP7 in MDA-231 cells inhibited de novo formation and progression of osteolytic bone metastases and, hence, their metastatic capability.
  • [MeSH-major] Bone Morphogenetic Proteins / biosynthesis. Bone Morphogenetic Proteins / pharmacology. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology
  • [MeSH-minor] Animals. Bone Morphogenetic Protein 7. Cell Line, Tumor. Disease Progression. Epithelial Cells / pathology. Female. Humans. Mesoderm / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retrospective Studies. Signal Transduction. Transforming Growth Factor beta / metabolism. Xenograft Model Antitumor Assays


76. Lear W, Mittmann N, Barnes E, Breen D, Murray C: Cost comparisons of managing complex facial basal cell carcinoma: Canadian study. J Cutan Med Surg; 2008 Mar-Apr;12(2):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost comparisons of managing complex facial basal cell carcinoma: Canadian study.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignancy and accounts for over 60,000 new cases of cancer in Canada annually.
  • All were located on the head and neck and were either recurrent disease or located in "at risk" sites such as the eye, ear, lip, or nose.
  • Although we did notice a trend toward greater costs in patients with recurrent disease, in males, younger patients, and tumors present for > 1 year, these did not reach significance within our sample size.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Cost of Illness. Facial Neoplasms / economics. Mohs Surgery / economics. Skin Neoplasms / economics
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / economics. Ontario. Radiotherapy / economics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346405.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, Briscoe DM: CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol; 2008 Dec 1;181(11):8088-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In additions, we found that basal levels of phosphorylated Akt as well as VEGF were increased in EC transfected with the raptor siRNA.
  • Together, these observations indicate that mTORC2 and Akt facilitate CD40-inducible expression of VEGF in EC, which is of clinical importance in tumor growth and the progression of chronic inflammatory diseases.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2007 Aug 31;282(35):25604-12 [17599906.001]
  • [Cites] Gut. 2007 Sep;56(9):1248-56 [17317789.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3801-8 [11090063.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 23;281(2):562-8 [11181084.001]
  • [Cites] J Allergy Clin Immunol. 2001 Feb;107(2):295-301 [11174196.001]
  • [Cites] Cell Mol Life Sci. 2001 Jan;58(1):4-43 [11229815.001]
  • [Cites] Am J Gastroenterol. 2001 Mar;96(3):822-8 [11280558.001]
  • [Cites] Circulation. 2002 May 28;105(21):2524-30 [12034660.001]
  • [Cites] Genes Dev. 2002 Jun 15;16(12):1472-87 [12080086.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7004-14 [12242281.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18008-14 [12637493.001]
  • [Cites] Transplantation. 2003 Jul 15;76(1):224-30 [12865814.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1534-41 [12874247.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7503-9 [15187129.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Sep;287(3):F512-20 [15140761.001]
  • [Cites] Cell. 1993 Jan 29;72(2):291-300 [7678782.001]
  • [Cites] Science. 1993 Sep 3;261(5126):1328-30 [7689748.001]
  • [Cites] Immunity. 1994 Aug;1(5):423-31 [7882172.001]
  • [Cites] Immunity. 1995 Jun;2(6):645-53 [7540943.001]
  • [Cites] Nature. 1995 Dec 7;378(6557):617-20 [8524395.001]
  • [Cites] Nature. 1995 Dec 7;378(6557):620-3 [8524396.001]
  • [Cites] Cell Immunol. 1995 Dec;166(2):196-206 [7497521.001]
  • [Cites] J Immunol. 1996 Jan 1;156(1):8-11 [8598498.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2129-42 [8642323.001]
  • [Cites] Science. 1996 Sep 27;273(5283):1864-7 [8791592.001]
  • [Cites] Immunol Res. 1997 Feb;16(1):59-70 [9048208.001]
  • [Cites] Transplantation. 1997 Dec 27;64(12):1765-74 [9422418.001]
  • [Cites] Nature. 1998 Feb 5;391(6667):591-4 [9468137.001]
  • [Cites] Transplantation. 1999 Jun 27;67(12):1590-9 [10401767.001]
  • [Cites] Transplantation. 1999 Jun 27;67(12):1626-31 [10401773.001]
  • [Cites] EXS. 2005;(94):209-31 [15617481.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):3098-107 [16493069.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):159-70 [16904613.001]
  • [Cites] J Exp Med. 2006 Oct 30;203(11):2441-50 [17043144.001]
  • [Cites] J Exp Med. 2006 Oct 30;203(11):2409-12 [17043147.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5070-5 [17545582.001]
  • [Cites] J Biol Chem. 2007 Jul 13;282(28):20534-43 [17502379.001]
  • [Cites] Biochem J. 2007 Aug 1;405(3):513-22 [17461779.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23679-86 [17553806.001]
  • [Cites] Lab Invest. 2000 Aug;80(8):1195-205 [10950110.001]
  • (PMID = 19018001.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI046756; None / None / / R01 AI046756-06A1; United States / NIAID NIH HHS / AI / AI046756; United States / NIAID NIH HHS / AI / R01 AI046756-06A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Anti-Bacterial Agents; 0 / Antigens, CD40; 0 / CRTC2 protein, human; 0 / Carrier Proteins; 0 / EIF4EBP1 protein, human; 0 / Multiprotein Complexes; 0 / Phosphoproteins; 0 / Proteins; 0 / RICTOR protein, human; 0 / RNA, Small Interfering; 0 / RPTOR protein, human; 0 / Transcription Factors; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / mechanistic target of rapamycin complex 1; 147205-72-9 / CD40 Ligand; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS312679; NLM/ PMC3495983
  •  go-up   go-down


78. Lagirand-Cantaloube J, Laud K, Lilienbaum A, Tirode F, Delattre O, Auclair C, Kryszke MH: EWS-FLI1 inhibits TNFalpha-induced NFkappaB-dependent transcription in Ewing sarcoma cells. Biochem Biophys Res Commun; 2010 Sep 3;399(4):705-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To exert its oncogenic function, EWS-FLI1 acts as an aberrant transcription factor, broadly altering the gene expression profile of tumor cells.
  • Nuclear factor-kappaB (NFkappaB) is a tightly regulated transcription factor controlling cell survival, proliferation and differentiation, as well as tumorigenesis.
  • NFkappaB activity is very low in unstimulated Ewing sarcoma cells, but can be induced in response to tumor necrosis factor (TNF).
  • We wondered whether NFkappaB activity could be modulated by EWS-FLI1 in Ewing sarcoma.
  • Using a knockdown approach in Ewing sarcoma cells, we demonstrated that EWS-FLI1 has no influence on NFkappaB basal activity, but impairs TNF-induced NFkappaB-driven transcription, at least in part through inhibition of NFkappaB binding to DNA.
  • Our findings suggest that, besides directly controlling the activity of its primary target promoters, EWS-FLI1 can also indirectly influence gene expression in tumor cells by modulating the activity of key transcription factors such as NFkappaB.
  • [MeSH-major] Bone Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Oncogene Proteins, Fusion / metabolism. Proto-Oncogene Protein c-fli-1 / metabolism. Sarcoma, Ewing / genetics. Transcription Factor RelA / metabolism
  • [MeSH-minor] Cell Line, Tumor. Electrophoretic Mobility Shift Assay. Genes, Reporter. Humans. Luciferases / genetics. RNA-Binding Protein EWS. Transcription, Genetic. Tumor Necrosis Factor-alpha / pharmacology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20691659.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Transcription Factor RelA; 0 / Tumor Necrosis Factor-alpha; EC 1.13.12.- / Luciferases
  •  go-up   go-down


79. Sun J, Stetler-Stevenson WG: Overexpression of tissue inhibitors of metalloproteinase 2 up-regulates NF-kappaB activity in melanoma cells. J Mol Signal; 2009 Jul 23;4:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Matrix Metalloproteinase functions in the remodeling of the extracellular matrix that is integral for many normal and pathological processes such as morphogenesis, angiogenesis, tissue repair, and tumor invasion.
  • However, it is not clear whether the TIMP-2 expression regulates the NF-kappaB pathway.
  • In this study, we have used stable melanoma cell lines, parental A2058, A2058T2-1 overexpressing TIMP-2, and A2058T2R-7 underexpressing TIMP-2, to determine the TIMP-2 regulation of the NF-kappaB activity.
  • TIMP-2 overexpressed cells had the lower basal level of IkappaBalpha, the inhibitor of NF-kappaB, compared to the parental A2058 cells.
  • In contrast, A2058T2R-7 underexpressing TIMP-2 had the similar NF-kappaB activity as that in the parental A2058 cell.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 May;5(5):1197-202 [10353757.001]
  • [Cites] Cytokines Cell Mol Ther. 2000 Mar;6(1):9-17 [10976534.001]
  • [Cites] FEBS Lett. 1996 Oct 28;396(1):103-7 [8906876.001]
  • [Cites] Exp Cell Res. 1996 Apr 10;224(1):110-5 [8612674.001]
  • [Cites] EMBO J. 1995 Mar 1;14(5):908-17 [7534227.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13453-9 [7768948.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Stroke. 2004 Jun;35(6):e159-62 [15105518.001]
  • [Cites] Trends Immunol. 2004 Jun;25(6):280-8 [15145317.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Jul;111(1-2):37-40 [18515093.001]
  • [Cites] Sci Signal. 2008;1(27):re6 [18612141.001]
  • [Cites] Exp Cell Res. 2007 Feb 1;313(3):551-9 [17141217.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):683-94 [16940160.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):301-13 [15986139.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G129-37 [15790758.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30353-6 [10521409.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Aug;36(8):1655-63 [15147743.001]
  • [Cites] Trends Cell Biol. 2004 Feb;14(2):64-9 [15102437.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):193-9 [15013524.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):3032-9 [9230219.001]
  • (PMID = 19627587.001).
  • [ISSN] 1750-2187
  • [Journal-full-title] Journal of molecular signaling
  • [ISO-abbreviation] J Mol Signal
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK075386-03; United States / NIDDK NIH HHS / DK / K01 DK075386; United States / NIDDK NIH HHS / DK / K01 DK075386-03
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2720935
  •  go-up   go-down


80. van Oosten EJ, Kuijpers DI, Thissen MR: Different pain sensations in photodynamic therapy of nodular basal cell carcinoma Results from a prospective trial and a review of the literature. Photodiagnosis Photodyn Ther; 2006 Mar;3(1):61-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different pain sensations in photodynamic therapy of nodular basal cell carcinoma Results from a prospective trial and a review of the literature.
  • BACKGROUND: Pain is a major side effect of topical photodynamic therapy (PDT), a relatively new and non-invasive treatment for particular types of basal cell carcinoma (BCC).
  • Furthermore, we studied if gender, tumour size and localization as well as different light sources with comparable wavelengths had an influence on the pain.
  • Gender as well as tumour localization and size did not alter the pain scores.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25049028.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


81. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Sveinsdottir SG, Magnusson V, Lindblom A, Kostulas K, Botella-Estrada R, Soriano V, Juberías P, Grasa M, Saez B, Andres R, Scherer D, Rudnai P, Gurzau E, Koppova K, Kiemeney LA, Jakobsdottir M, Steinberg S, Helgason A, Gretarsdottir S, Tucker MA, Mayordomo JI, Nagore E, Kumar R, Hansson J, Olafsson JH, Gulcher J, Kong A, Thorsteinsdottir U, Stefansson K: ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet; 2008 Jul;40(7):886-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.
  • Fair color increases risk of cutaneous melanoma (CM) and basal cell carcinoma (BCC).
  • [MeSH-major] Agouti Signaling Protein / genetics. Carcinoma, Basal Cell / genetics. Melanoma / genetics. Monophenol Monooxygenase / genetics. Pigmentation / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Europe. Eye Color / genetics. Gene Frequency. Genetic Predisposition to Disease. Humans. Membrane Glycoproteins / genetics. Middle Aged. Neoplasm Metastasis. Odds Ratio. Oxidoreductases / genetics. Polymorphism, Single Nucleotide. Receptor, Melanocortin, Type 1 / genetics. Registries


82. Tuncel M, Aydin D, Yaman E, Tazebay UH, Güç D, Doğan AL, Taşbasan B, Uğur O: The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake. Cancer Biother Radiopharm; 2007 Jun;22(3):443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to comparatively investigate the effects of 5-azacytidine-C (5-Aza), trichostatin-A (TSA), and all-trans retinoic acid (ATRA) on the mRNA expressions of the sodium and iodine (Na/I) symporter (NIS), thyroglobulin (Tg), thyroid peroxidase (TPO), and the thyroid-stimulating hormone receptor (TSH-R), as well as radioiodine (RAI) uptake in cancer (B-CPAP) and normal (Nthy-ori 3-1) thyroid cell lines.
  • Cell lines were treated with 10 ng/mL of TSA, 5 microM of 5-AZA, and 1 microM of ATRA, according to the MTT (methyl-thiazol-tetrazolium) test results.
  • Following the treatment, NIS, Tg, TPO, and TSH-R mRNA levels were detected by real-time-polymerase chain reaction (RT-PCR) and RAI uptakes were measured by using a well counter as counts/cell number.
  • 5-Aza increased TSH-R mRNA expression in both of the cell lines and decreased TPO, NIS, and Tg mRNA levels in the cancer cell line.
  • In the normal thyroid cell line, 5-AZA increased TPO mRNA levels by 2-fold and made no differences in NIS and Tg mRNA levels.
  • TSA treatment repressed NIS and Tg mRNA levels and made no change on other thyroid-specific genes that were investigated in the cancer cell line.
  • In the normal thyroid cell line, TSA increased TSH-R mRNA levels in 72 hours and created no important difference in the other genes.
  • ATRA repressed the TSH-R mRNA levels in the normal thyroid cell line and increased the TPO and Tg mRNA levels slightly in both the cell lines.
  • Furthermore, in short-term treatment, ATRA repressed the NIS gene expression slightly, but in the long term, this repression turned to basal levels.
  • 5-Aza, TSA, and ATRA did not make any changes in RAI uptake in the cancer cell line, but rTSH increased RAI uptake significantly.
  • In the normal thyroid cell line, TSA and ATRA decreased RAI uptake (to 1/10 and 1/2, respectively), but 5-Aza and rTSH increased RAI uptake significantly (2- and 4-fold, respectively).
  • [MeSH-major] Gene Expression Regulation / drug effects. Gene Expression Regulation / genetics. Iodine Radioisotopes / pharmacokinetics. Proteins / genetics. Thyroid Gland / metabolism. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Aged. Apoptosis / radiation effects. Azacitidine / pharmacology. Cell Line, Tumor. Humans. Hydroxamic Acids / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Time Factors. Tretinoin / pharmacology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Biother Radiopharm. 2007 Dec;22(6):863
  • (PMID = 17679169.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Comparative Study; Duplicate Publication; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / Iodine Radioisotopes; 0 / Proteins; 0 / RNA, Messenger; 5688UTC01R / Tretinoin; M801H13NRU / Azacitidine
  •  go-up   go-down


83. Amoresano A, Di Costanzo A, Leo G, Di Cunto F, La Mantia G, Guerrini L, Calabrò V: Identification of DeltaNp63alpha protein interactions by mass spectrometry. J Proteome Res; 2010 Apr 05;9(4):2042-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • p63, a transcription factor related to the p53 tumor suppressor, plays a key role in epidermal differentiation and limb development.
  • It supports the regenerative capacity of basal keratinocytes and its upregulation is a hallmark of human squamous carcinomas.
  • The finding that DeltaNp63alpha exists in complexes with several RNA-binding proteins lays the premises for the analysis of the role of DeltaNp63alpha in mRNA metabolism and transport.
  • [MeSH-major] Protein Interaction Mapping / methods. Tandem Mass Spectrometry / methods. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cluster Analysis. Databases, Protein. Heterogeneous-Nuclear Ribonucleoproteins / chemistry. Heterogeneous-Nuclear Ribonucleoproteins / metabolism. Humans. Protein Isoforms. Proteins / chemistry. Proteins / metabolism. RNA-Binding Protein FUS / chemistry. RNA-Binding Protein FUS / metabolism. Transcription Factors

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085233.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP05056
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heterogeneous-Nuclear Ribonucleoproteins; 0 / Protein Isoforms; 0 / Proteins; 0 / RNA-Binding Protein FUS; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


84. Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjær SK: Trends in the incidence of nonmelanoma skin cancer in Denmark 1978-2007: Rapid incidence increase among young Danish women. Int J Cancer; 2010 Nov 1;127(9):2190-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were obtained from the Danish Cancer Registry and the Danish Registry of Pathology.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473901.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Yoon J, Jung SY, Ahn B, Heo K, Jin S, Iyoda T, Yoshida H, Ree M: Order-order and order-disorder transitions in thin films of an amphiphilic liquid crystalline diblock copolymer. J Phys Chem B; 2008 Jul 24;112(29):8486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Order-order and order-disorder transitions in thin films of an amphiphilic liquid crystalline diblock copolymer.
  • In this study, we quantitatively investigated the temperature-dependent phase transition behaviors of thin films of an interesting amphiphilic diblock copolymer, poly(ethylene oxide)-b-poly(11-[4-(4-butylphenylazo)phenoxy]undecyl methacrylate) (p(EO)-b-p(MAAZ)) and the resulting morphological structures by using synchrotron grazing incidence X-ray scattering (GIXS) and differential scanning calorimetry.
  • The quantitative GIXS analysis showed that the diblock copolymer in the homogeneous, isotropic melt state undergoes phase-separation near 190 degrees C and then forms a body-centered cubic (BCC) structure of spherical p(EO) domains in the p(MAAZ) matrix, at which point the p(EO) domains and the p(MAAZ) matrix are both in amorphous, liquid states.
  • The BCC structure of spherical p(EO) domains is converted to a hexagonal cylinder structure near 120 degrees C, which is induced by the transformation of the isotropic phase of the p(MAAZ) matrix to the smectic A phase, which is composed of a laterally ordered structure of p(MAAZ) blocks with fully extended side groups.
  • The resulting hexagonal cylinder structure is very stable below 120 degrees C.
  • This microscopic hexagonal cylinder structure is retained as the smectic A phase of the p(MAAZ) matrix undergoes further transitions to smectic C near 104 degrees C and to a smectic X phase near 76 degrees C, while the amorphous, liquid phase of the p(EO) cylinders undergoes crystallization near -15 degrees C.
  • These complicated temperature-dependent disorder-order and order-order phase transitions in the films were found to take place reversibly during the heating run.
  • A face-centered orthorhombic structure of p(EO) domains was also found during the heating run and is an intermediate structure in the hexagonal cylinder structure to BCC structure transformation.
  • We use these structural analysis results to propose molecular structure models at various temperatures for thin films of the diblock polymer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588338.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Heretsch P, Tzagkaroulaki L, Giannis A: Modulators of the hedgehog signaling pathway. Bioorg Med Chem; 2010 Sep 15;18(18):6613-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Today it is regarded as a key regulator in embryogenesis where it governs processes like cell proliferation, differentiation, and tissue patterning.
  • But hh signaling has a second-much darker-face: it plays an important role in several types of human cancers where it promotes growth and enables proliferation of tumor stem cells.
  • The etiology of medulloblastoma and basal cell carcinoma is tightly linked to aberrant hh activity, but also cancers of the prostate, the pancreas, the colon, the breasts, rhabdomyosarcoma, and leukemia, are dependent on irregular hh activity.
  • In this review we will trace the story of cyclopamine, give an overview on the biological modes of hh signaling both in untransformed and malignant cells, and finally present potent modulators of the hh pathway-many of them already in clinical studies.
  • [MeSH-major] Hedgehog Proteins / metabolism. Neoplasms / metabolism. Signal Transduction

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20708941.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  •  go-up   go-down


87. Sane RS, Buckley DJ, Buckley AR, Nallani SC, Desai PB: Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells. Drug Metab Dispos; 2008 May;36(5):946-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously we observed that the antiestrogens tamoxifen and 4-hydroxytamoxifen (4OHT) induce CYP3A4 in primary human hepatocytes and activate human pregnane X receptor (PXR) in cell-based reporter assays.
  • We then used cell-based reporter assay to evaluate the effects of other receptors such as glucocorticoid receptor GR alpha and estrogen receptor ER alpha on the transcriptional activation of PXR.
  • On the other hand, the presence of ER alpha inhibited PXR-mediated basal activation of CYP3A4 promoter, possibly via competing for common cofactors such as steroid receptor coactivator 1 and glucocorticoid receptor interacting protein 1.
  • [MeSH-minor] Cell Line, Tumor. Cells, Cultured. Estrogen Receptor alpha / metabolism. Hepatocytes / drug effects. Hepatocytes / metabolism. Humans. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. Receptors, Glucocorticoid / metabolism. Transfection

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858399 for PMID:18299335 [PharmGKB] .
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299335.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Glucocorticoid; 0 / Receptors, Steroid; 0 / pregnane X receptor; 094ZI81Y45 / Tamoxifen; 17197F0KYM / afimoxifene; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


88. Panizzon RG: [Dermatologic radiotherapy]. Hautarzt; 2007 Aug;58(8):701-10, quiz 711
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Another important parameter is the half-value depth which should correspond to the depth of the tumor below the skin surface.
  • Indications for radiotherapy of malignant skin tumors include basal cell carcinoma, squamous cell carcinoma, severe actinic keratoses, lentigo maligna, lentigo maligna melanoma, Merkel cell carcinoma, and Kaposi sarcoma, as well as T- and B-cell lymphomas.
  • Most patients with malignant skin tumors require life-long monitoring after radiotherapy.
  • The most common benign lesions where radiotherapy may be indicated are eczemas, psoriasis, and keloids, but its use should be carefully weighed in these settings.
  • [MeSH-major] Precancerous Conditions / radiotherapy. Skin Diseases / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Eczema / radiotherapy. Humans. Keloid / radiotherapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell, Cutaneous / radiotherapy. Palliative Care. Psoriasis / radiotherapy. Radiotherapy Dosage. Sarcoma, Kaposi / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639284.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Ljuca D, Fatusić Z, Iljazović E, Ahmetović B: Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Bosn J Basic Med Sci; 2007 May;7(2):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasion and metastasis of solid tumors request protease activity resulting in basal membrane destruction and surrounding matrix.
  • In that process, urokinase plasminogen activator (uPA) and its receptor, urokinase plasminogen activator receptor (suPAR) play a key role, that via plasmin activation lead to basal membrane and matrix degradation in surrounding of the tumor, enable to its invasion and metastasis.
  • Determination of serum concentration of those tumor markers can be useful in preoperative as well as in postoperative period.
  • In late 1950s and ear1y 1960s, when it was found out that malignant ovarian tumors were chemosensitive, their chemotherapy treatment has begun.
  • Aim of this study was to determine serum uPA, suPAR and CEA in FIGO II and III patients with different histological type (serous, mucinous, clear cell tumor) before and after PT chemotherapy protocol during following three cycles.
  • Results of this study have shown that uPA, suPAR and CEA met criteria for prognostic markers for monitoring of successfulness of platina/taxol chemotherapy protocol for serous, mucinous and clear cell tumor FIGO II and III stage of ovarian carcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489744.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; BG3F62OND5 / Carboplatin; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


90. Freier K, Flechtenmacher C, Devens F, Hartschuh W, Hofele C, Lichter P, Joos S: Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol Rep; 2006 May;15(5):1141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma.
  • Formation of basal cell carcinoma (BCC) has been linked to deregulation in the sonic hedgehogh (Shh) signalling pathway.
  • To assess the expression of Nmyc protein and gene copy numbers of the NMYC gene locus in a representative BCC tumour collection, immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) were performed on 273 BCC specimens of different growth patterns and anatomic localisations on tissue microarray (TMA) sections.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Dosage. Genes, myc / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596176.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


91. Hansen C, Wilkinson D, Hansen M, Soyer HP: Factors contributing to incomplete excision of nonmelanoma skin cancer by Australian general practitioners. Arch Dermatol; 2009 Nov;145(11):1253-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study rates of incomplete excision of basal (BCC) and squamous (SCC) cell cancer by Australian general practitioners with a special interest.
  • MAIN OUTCOME MEASURES: Rates of incomplete excision according to physician, clinic, anatomic location of the lesion, and whether a previous biopsy had been performed.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Clinical Competence. Dermatology / methods. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917954.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. McCluggage WG, Ganesan R, Hirschowitz L, Miller K, Rollason TP: Ectopic prostatic tissue in the uterine cervix and vagina: report of a series with a detailed immunohistochemical analysis. Am J Surg Pathol; 2006 Feb;30(2):209-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The latter is the first reported example of benign prostatic tissue in the vagina.
  • In the glandular areas, a double cell layer of luminal and basal cells was focally apparent.
  • Immunohistochemical staining with the high molecular weight cytokeratin 34betaE12 highlighted the basal cell layer, which often extended into the center of the cellular islands, reminiscent of basal cell hyperplasia involving the prostate gland.
  • All cases tested were CD10 positive (largely restricted to the basal cell layer), alpha-methylacyl-CoA racemase positive, and p16 negative.
  • Ectopic prostatic tissue in the lower female genital tract is almost certainly a benign condition, based on the morphology, including the presence of a double cell layer, although follow-up of larger numbers of cases is required.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervix Uteri / pathology. Prostate. Uterine Diseases / pathology. Vaginal Diseases / pathology


93. Yin P, Lin Z, Reierstad S, Wu J, Ishikawa H, Marsh EE, Innes J, Cheng Y, Pearson K, Coon JS 5th, Kim JJ, Chakravarti D, Bulun SE: Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res; 2010 Feb 15;70(4):1722-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine leiomyoma is the most common tumor of the female genital tract and the leading cause of hysterectomy.
  • Luciferase reporter assays showed significant baseline and RU486-inducible promoter activity in the KLF11 basal promoter or distal PR-binding region, both of which contained multiple Sp1-binding sequences but lacked classic progesterone response elements.
  • RU486 stimulated recruitment of Sp1, RNA polymerase II, PR, and the coactivators SRC-1 and SRC-2 to the distal region and basal promoter. siRNA knockdown of PR increased KLF11 expression, whereas knockdown of KLF11 increased leiomyoma cell proliferation and abolished the antiproliferative effect of RU486.

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 1999 Jul 20;153(1-2):11-7 [10459849.001]
  • [Cites] Science. 1998 Jul 3;281(5373):60-3 [9679020.001]
  • [Cites] Nucleic Acids Res. 2004;32(22):6627-35 [15608294.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):953-61 [15572421.001]
  • [Cites] Endocr Rev. 2005 May;26(3):423-38 [15857972.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1584-92 [15831516.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21491-7 [15790569.001]
  • [Cites] Cell. 2005 Jul 15;122(1):33-43 [16009131.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):8150-65 [16135805.001]
  • [Cites] FEBS Lett. 2005 Oct 24;579(25):5535-41 [16216245.001]
  • [Cites] Mol Endocrinol. 2006 Jan;20(1):45-55 [16141356.001]
  • [Cites] J Biol Chem. 2006 Feb 3;281(5):2585-97 [16303757.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1296-304 [16464945.001]
  • [Cites] Mol Hum Reprod. 2006 Mar;12(3):187-207 [16524927.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2278-91 [16740655.001]
  • [Cites] Nat Genet. 2006 Nov;38(11):1289-97 [17013392.001]
  • [Cites] Obstet Gynecol. 2006 Dec;108(6):1381-7 [17138770.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):616-23 [17105846.001]
  • [Cites] Mol Endocrinol. 2007 Mar;21(3):635-50 [17192405.001]
  • [Cites] Mol Cell Endocrinol. 2007 Mar 15;267(1-2):106-15 [17275994.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5017-24 [17510434.001]
  • [Cites] Endocrinology. 2007 Sep;148(9):4238-50 [17556502.001]
  • [Cites] Maturitas. 2009 Apr 20;62(4):334-7 [19231117.001]
  • [Cites] Genomics. 1999 Dec 1;62(2):297-303 [10610726.001]
  • [Cites] Circ Res. 2000 Jan 7-21;86(1):15-23 [10625300.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):31655-60 [10915796.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3209-14 [11050005.001]
  • [Cites] Mol Cell Endocrinol. 2001 May 15;176(1-2):97-102 [11369448.001]
  • [Cites] Mol Cell Endocrinol. 2002 Jun 28;192(1-2):45-53 [12088866.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]
  • [Cites] Mol Hum Reprod. 2002 Dec;8(12):1071-8 [12468639.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29769-75 [12782625.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4748-58 [12970187.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7920-5 [14560034.001]
  • [Cites] Steroids. 2003 Nov;68(10-13):817-24 [14667973.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Dec;87(4-5):233-40 [14698203.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1701-12 [15082697.001]
  • [Cites] Semin Reprod Med. 2004 May;22(2):113-9 [15164306.001]
  • [Cites] Genome Biol. 2004;5(9):R66 [15345050.001]
  • [Cites] Int J Gynecol Pathol. 1985;4(2):89-96 [3926664.001]
  • [Cites] Am J Obstet Gynecol. 1989 Mar;160(3):637-41 [2929683.001]
  • [Cites] Endocrinology. 1992 Mar;130(3):1716-27 [1311246.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jul;169(1):78-85 [8333481.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15175-81 [8663058.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):293-9 [8989276.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Jul;62(4):243-52 [9408078.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):442-9 [9418891.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10696-701 [9553133.001]
  • [Cites] Genes Dev. 1999 Oct 1;13(19):2465-77 [10521391.001]
  • (PMID = 20124487.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD057877-01A25576; United States / NICHD NIH HHS / HD / P01HD057877; United States / NCRR NIH HHS / RR / UL1 RR025741; United States / NICHD NIH HHS / HD / P01 HD057877-01A2; United States / NICHD NIH HHS / HD / HD057877-01A25576; United States / NICHD NIH HHS / HD / HD057877-01A2; United States / NICHD NIH HHS / HD / P01 HD057877; United States / NICHD NIH HHS / HD / R01 HD046260
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Hormone Antagonists; 0 / KLF11 protein, human; 0 / Receptors, Progesterone; 0 / Repressor Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 320T6RNW1F / Mifepristone; 4G7DS2Q64Y / Progesterone
  • [Other-IDs] NLM/ NIHMS167267; NLM/ PMC2822899
  •  go-up   go-down


94. Wettstein R, Erba P, Farhadi J, Kalbermatten DF, Arnold A, Haug M, Pierer G: Incomplete excision of basal cell carcinoma in the subunits of the nose. Scand J Plast Reconstr Surg Hand Surg; 2008;42(2):92-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma in the subunits of the nose.
  • Reconstructive procedures after resection of nasal basal cell carcinoma (BCC) vary depending on the subunit involved.
  • This, however, was not the result of poor estimation of the extent of the tumour and reluctance to excise more challenging areas widely for reconstruction, but to the method chosen to eradicate the tumour.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18335353.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Golonzhka O, Leid M, Indra G, Indra AK: Expression of COUP-TF-interacting protein 2 (CTIP2) in mouse skin during development and in adulthood. Gene Expr Patterns; 2007 Aug;7(7):754-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CTIP2 expression in the ectoderm was first detected at embryonic day 10.5 (E10.5), and became increasingly restricted to proliferating cells of the basal cell layer of the developing epidermis in later stages of fetal development and in adult skin.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 2005 Jan 20;45(2):207-21 [15664173.001]
  • [Cites] Cell Prolif. 1994 May;27(5):279-89 [10465012.001]
  • [Cites] J Biol Chem. 2006 Oct 27;281(43):32272-83 [16950772.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 6;355(2):538-42 [17306224.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1431-3 [10688782.001]
  • [Cites] J Biol Chem. 2000 Apr 7;275(14):10315-22 [10744719.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13473-5 [11087834.001]
  • [Cites] Biochem J. 2002 Dec 1;368(Pt 2):555-63 [12196208.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Feb 7;301(2):598-603 [12565905.001]
  • [Cites] J Anat. 2003 Jan;202(1):113-23 [12587926.001]
  • [Cites] J Invest Dermatol. 2003 Apr;120(4):501-11 [12648211.001]
  • [Cites] Nat Immunol. 2003 Jun;4(6):533-9 [12717433.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43041-50 [12930829.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):963-8 [14708593.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):393-4 [15060550.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Feb;149(1):72-6 [15104287.001]
  • [Cites] Gene Expr Patterns. 2004 Oct;4(6):733-9 [15465497.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Mar;86(5):1563-7 [2466292.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1329-37 [2364430.001]
  • [Cites] J Invest Dermatol. 1993 Jul;101(1 Suppl):16S-26S [8326150.001]
  • [Cites] J Cell Biol. 1993 Nov;123(3):513-22 [8227122.001]
  • [Cites] Development. 1994 Sep;120(9):2369-83 [7525178.001]
  • [Cites] Blood. 1996 Jan 1;87(1):1-13 [8547630.001]
  • [Cites] Birth Defects Res C Embryo Today. 2005 Dec;75(4):314-29 [16425252.001]
  • (PMID = 17631058.001).
  • [ISSN] 1567-133X
  • [Journal-full-title] Gene expression patterns : GEP
  • [ISO-abbreviation] Gene Expr. Patterns
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES00510; United States / NIGMS NIH HHS / GM / GM60852; United States / NIGMS NIH HHS / GM / R01 GM060852; United States / NIGMS NIH HHS / GM / R01 GM060852-01A2; United States / NIGMS NIH HHS / GM / GM060852-01A2; United States / NIEHS NIH HHS / ES / P30 ES000210
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Bcl11b protein, mouse; 0 / DNA-Binding Proteins; 0 / Keratin-15; 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ NIHMS29611; NLM/ PMC2063996
  •  go-up   go-down


96. Bortolotti C, Kunit T, Moder A, Hufnagl C, Schmidt S, Hartl A, Langelueddecke C, Fürst J, Geibel JP, Ritter M, Jakab M: The phytostilbene resveratrol induces apoptosis in INS-1E rat insulinoma cells. Cell Physiol Biochem; 2009;23(4-6):245-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the effect of resveratrol on proliferation and induction of apoptosis of INS-1E rat insulinoma cells by cell counting, crystal violet staining, flow cytometry and immunoblotting.
  • Resveratrol treatment of INS-1E cells at concentrations > or =50 microM resulted in a dose-dependent inhibition of cell proliferation, accumulation of the cells in the S and G0/G1 phase and a significant increase of the percentage of apoptotic cells.
  • This was paralleled by an increase of cell granularity, apoptotic volume decrease (AVD), exposure of phosphatidylserine at the outer leaflet of the plasma membrane, an increase of the 7-AAD signal and caspase activation.
  • The AMP-kinase (AMPK) inhibitor compound C (10 microM) significantly inhibited cell proliferation and induced caspase activation within 48 hours but this effect was not modified by resveratrol suggesting that AMPK is not a major target involved in mediating the proapoptotic effect of resveratrol in INS-1E cells.
  • Addition of insulin (10 microM) to the culture medium strongly enhanced basal Akt phosphorylation.
  • [MeSH-minor] Animals. Caspases / metabolism. Cell Cycle. Cell Line, Tumor. Dactinomycin / analogs & derivatives. Dactinomycin / metabolism. Dactinomycin / pharmacology. Insulin / pharmacology. Insulinoma. Pancreatic Neoplasms. Phosphatidylserines / metabolism. Phosphatidylserines / pharmacology. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Rats. Signal Transduction. Time Factors

  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. RESVERATROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19471092.001).
  • [ISSN] 1421-9778
  • [Journal-full-title] Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • [ISO-abbreviation] Cell. Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Insulin; 0 / Phosphatidylserines; 0 / Stilbenes; 1CC1JFE158 / Dactinomycin; 7240-37-1 / 7-aminoactinomycin D; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / Caspases; Q369O8926L / resveratrol
  •  go-up   go-down


97. Ly NP, Komatsuzaki K, Fraser IP, Tseng AA, Prodhan P, Moore KJ, Kinane TB: Netrin-1 inhibits leukocyte migration in vitro and in vivo. Proc Natl Acad Sci U S A; 2005 Oct 11;102(41):14729-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell migration plays important roles in embryonic development and inflammation, and this process is highly regulated to ensure tissue homeostasis.
  • However, active signals also are likely to exist that can repulse cells or abolish existing cell migration.
  • The ability of the guidance molecule netrin-1 to repulse or abolish attraction of neuronal cells expressing the UNC5b receptor makes it an attractive candidate for the regulation of inflammatory cell migration.
  • These data suggest that endothelial expression of netrin-1 may inhibit basal cell migration into tissues and that its down-regulation with the onset of sepsis/inflammation may facilitate leukocyte recruitment.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2000 Jan;127(1):13-22 [10654596.001]
  • [Cites] Cell. 1994 Aug 12;78(3):425-35 [8062385.001]
  • [Cites] J Intern Med. 2001 Aug;250(2):91-104 [11489059.001]
  • [Cites] Nat Neurosci. 2001 Nov;4 Suppl:1169-76 [11687826.001]
  • [Cites] Neuron. 2001 Nov 20;32(4):605-17 [11719202.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):898-905 [12359238.001]
  • [Cites] Dev Cell. 2003 Mar;4(3):371-82 [12636918.001]
  • [Cites] Gene Expr Patterns. 2003 Jun;3(3):279-83 [12799072.001]
  • [Cites] J Exp Med. 2003 Jun 16;197(12):1657-66 [12796468.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6519-26 [14662852.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9115-24 [14645233.001]
  • [Cites] Curr Biol. 2004 May 25;14(10):897-905 [15186747.001]
  • [Cites] Dev Growth Differ. 2004 Jun;46(3):275-82 [15206958.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):341-52 [15215188.001]
  • [Cites] Cell. 1994 Aug 12;78(3):409-24 [8062384.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):833-8 [9126742.001]
  • [Cites] Development. 1998 Jan;125(1):41-50 [9389662.001]
  • [Cites] Cell. 1999 Jun 25;97(7):927-41 [10399920.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):69-73 [10485706.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):5914-7 [15528323.001]
  • [Cites] Nature. 2001 Apr 19;410(6831):948-52 [11309622.001]
  • (PMID = 16203981.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG020255; United States / NHLBI NIH HHS / HL / 501 HL 58819-04; United States / NIA NIH HHS / AG / AG20255
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Nerve Growth Factors; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 0 / netrin receptors; 11062-77-4 / Superoxides; 158651-98-0 / netrin-1
  • [Other-IDs] NLM/ PMC1253572
  •  go-up   go-down


98. Hu Z, Huang G, Sadanandam A, Gu S, Lenburg ME, Pai M, Bayani N, Blakely EA, Gray JW, Mao JH: The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res; 2010;12(2):R18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However its role in tumor development remains largely unknown.
  • METHODS: We measured HJURP expression level in human breast cancer cell lines and primary breast cancers by Western blot and/or by Affymetrix Microarray; and determined its associations with clinical variables using standard statistical methods.
  • We assessed cell growth and apoptosis of breast cancer cells after radiation using high-content image analysis.
  • HJURP mRNA levels were significantly associated with estrogen receptor (ER), progesterone receptor (PR), Scarff-Bloom-Richardson (SBR) grade, age and Ki67 proliferation indices, but not with pathologic stage, ERBB2, tumor size, or lymph node status.
  • Higher HJURP mRNA levels significantly decreased disease-free and overall survival.
  • In a multivariate Cox proportional-hazard regression, including clinical variables as covariates, HJURP mRNA levels remained an independent prognostic factor for disease-free and overall survival.
  • In addition HJURP mRNA levels were an independent prognostic factor over molecular subtypes (normal like, luminal, Erbb2 and basal).
  • In vitro studies in breast cancer cell lines showed that cells with high HJURP levels were more sensitive to radiation treatment and had a higher rate of apoptosis than those with low levels.
  • CONCLUSIONS: HJURP mRNA level is a prognostic factor for disease-free and overall survival in patients with breast cancer and is a predictive biomarker for sensitivity to radiotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jan;119(2):335-46 [19266279.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Cell. 2003 Feb 21;112(4):407-21 [12600307.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43 [15701700.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):773-85 [16195750.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R953-64 [16280042.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10292-301 [17079448.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] Cell. 2007 Feb 23;128(4):647-50 [17320502.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3207-14 [17545524.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34 [17671126.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8544-53 [17823411.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):807-15 [17960622.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):1950-9 [18435926.001]
  • [Cites] J Cell Biochem. 2008 Aug 15;104(6):2040-58 [18425771.001]
  • [Cites] Nat Rev Genet. 2008 Dec;9(12):899-910 [18981989.001]
  • [Cites] BMC Mol Biol. 2009;10:17 [19257903.001]
  • [Cites] Cell. 2009 May 1;137(3):472-84 [19410544.001]
  • [Cites] Cell. 2009 May 1;137(3):485-97 [19410545.001]
  • [Cites] Cell. 2009 Jun 26;137(7):1173-4 [19563746.001]
  • [CommentIn] Breast Cancer Res. 2010;12(3):106 [20497617.001]
  • (PMID = 20211017.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116481; United States / NCI NIH HHS / CA / P50 CA 5820; United States / NCI NIH HHS / CA / P30 CA082103-010001; United States / NCI NIH HHS / CA / P30 CA082103; United States / NCI NIH HHS / CA / CA058207-09; United States / NCI NIH HHS / CA / U54 CA 112970; United States / NCI NIH HHS / CA / P30 CA 82103; United States / NCI NIH HHS / CA / P50 CA058207; United States / NCI NIH HHS / CA / U54 CA112970; United States / NCI NIH HHS / CA / P50 CA058207-09; United States / NCI NIH HHS / CA / U54 CA112970-01; United States / NCI NIH HHS / CA / CA112970-01; United States / NCI NIH HHS / CA / CA082103-010001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Holliday junction recognizing protein, human; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2879562
  •  go-up   go-down


99. Carvalho LV, Pereira EM, Frappart L, Boniol M, Bernardo WM, Tarricone V, Tavtigian S, Southey MC: Molecular characterization of breast cancer in young Brazilian women. Rev Assoc Med Bras (1992); 2010 May-Jun;56(3):278-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three intragenic BRCA1 locus microsatellites, D17S1322, D17S1323, and D17S855, were PCR amplified from matched normal (lymphocyte) and tumor DNAs for (LOH) analysis.
  • RESULTS: We found 13 cases (18%) that had an immunohistochemical profile consistent with being basal-like.
  • Forty cases (55%) were luminal A type; 11% (8 cases) were luminal B type, 13% (9 cases) were HER2-overexpressing tumors and two cases were ER-/HER2- carcinomas lacking basal marker expression.
  • Four of the 16 informative cases at D17S1322, one of the four informative cases at D17S855, and none of the five informative cases at D17S1323 displayed LOH (four basal-like and one Luminal A).
  • Microsatellite instability (MSI) at D17S855 and D17S1322 was found in two cases (one a basal-like and one Luminal A).
  • CONCLUSION: In our study, basal-like tumor was the second most frequent molecular type among young Brazilian women and was only observed in women diagnosed under the age of 35 years.
  • There was no significant difference of LOH at BRCA1 locus rates between basal-like breast tumors and not-basal-like breast tumors (p=0.62).
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Genes, BRCA1. Loss of Heterozygosity / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Brazil. Chi-Square Distribution. Female. Gene Expression Regulation, Neoplastic. Humans. Microsatellite Instability. Neoplasms, Basal Cell / genetics. Young Adult


100. Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, Gao YT, Zheng W, Colditz GA: Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst; 2008 Oct 1;100(19):1352-60
PDF icon [Fulltext service] Download